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A B S T R A C T
Background
Self-harm (SH; intentional self-poisoning or self-injury) is common, often repeated, and strongly associated with suicide. This is an
update of a broader Cochrane review on psychosocial and pharmacological treatments for deliberate SH, first published in 1998 and
previously updated in 1999. We have now divided the review into three separate reviews. This review is focused on pharmacological
interventions in adults who self harm.
Objectives
To identify all randomised controlled trials of pharmacological agents or natural products for SH in adults, and to conduct meta-
analyses (where possible) to compare the effects of specific treatments with comparison types of treatment (e.g., placebo/alternative
pharmacological treatment) for SH patients.
Search methods
For this update the Cochrane Depression, Anxiety and Neurosis Review Group (CCDAN) Trials Search Co-ordinator searched the
CCDAN Specialised Register (September 2014). Additional searches of MEDLINE, EMBASE, PsycINFO, and CENTRAL were
conducted to October 2013.
Selection criteria
We included randomised controlled trials comparing pharmacological treatments or natural products with placebo/alternative phar-
macological treatment in individuals with a recent (within six months) episode of SH resulting in presentation to clinical services.
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Data collection and analysis
We independently selected trials, extracted data, and appraised trial quality. For binary outcomes, we calculated odds ratios (ORs) and
their 95% confidence intervals (CIs). For continuous outcomes we calculated the mean difference (MD) and 95% CI. Meta-analysis
was only possible for one intervention (i.e. newer generation antidepressants) on repetition of SH at last follow-up. For this analysis, we
pooled data using a random-effects model. The overall quality of evidence for the primary outcome was appraised for each intervention
using the GRADE approach.
Main results
We included seven trials with a total of 546 patients. The largest trial included 167 participants. We found no significant treatment
effect on repetition of SH for newer generation antidepressants (n = 243; k = 3; OR 0.76, 95% CI 0.42 to 1.36; GRADE: low quality
of evidence), low-dose fluphenazine (n = 53; k = 1; OR 1.51, 95% CI 0.50 to 4.58; GRADE: very low quality of evidence), mood
stabilisers (n = 167; k = 1; OR 0.99, 95% CI 0.33 to 2.95; GRADE: low quality of evidence), or natural products (n = 49; k = 1; OR
1.33, 95% CI 0.38 to 4.62; GRADE: low quality of evidence). A significant reduction in SH repetition was found in a single trial of
the antipsychotic flupenthixol (n = 30; k = 1; OR 0.09, 95% CI 0.02 to 0.50), although the quality of evidence for this trial, according
to the GRADE criteria, was very low. No data on adverse effects, other than the planned outcomes relating to suicidal behaviour, were
reported.
Authors’ conclusions
Given the low or very low quality of the available evidence, and the small number of trials identified, it is not possible to make firm
conclusions regarding pharmacological interventions in SH patients. More and larger trials of pharmacotherapy are required. In view of
an indication of positive benefit for flupenthixol in an early small trial of low quality, these might include evaluation of newer atypical
antipsychotics. Further work should include evaluation of adverse effects of pharmacological agents. Other research could include
evaluation of combined pharmacotherapy and psychological treatment.
P L A I N L A N G U A G E S U M M A R Y
Drugs and natural products for self-harm in adults
Wehave reviewed the international literature regardingpharmacological (drug) and natural product (dietary supplementation) treatment
trials in this field. A total of seven trials meeting our inclusion criteria were identified. There is little evidence of beneficial effects of
either pharmacological or natural product treatments. However, few trials have been conducted and those that have are small, meaning
that possible beneficial effects of some therapies cannot be ruled out.
Why is this review important?
Self-harm (SH), which includes intentional self-poisoning/overdose and self-injury, is amajor problem inmany countries and is strongly
linked to suicide. It is therefore important that effective treatments for SH patients are developed. Whilst there has been an increase in
the use of psychosocial interventions for SH in adults (which is the focus of a separate review), drug treatments are frequently used in
clinical practice. It is therefore important to assess the evidence for their effectiveness.
Who will be interested in this review?
Clinicians working with patients who engage in SH, patients themselves, and their relatives.
What questions does this review aim to answer?
This review is an update of a previous Cochrane review from 1999 which found little evidence of beneficial effects of drug treatments
on repetition of SH apart from for flupenthixol. This update aims to further evaluate the evidence for effectiveness of drugs and natural
products for patients with SH with a broader range of outcomes.
Which studies were included in the review?
To be included in the review, studies had to be randomised controlled trials of drug treatments for adults who had recently engaged in
SH.
What does the evidence from the review tell us?
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There is currently no clear evidence for the effectiveness of antidepressants, antipsychotics, mood stabilisers, or natural products in
preventing repetition of SH.
What should happen next?
We recommend further trials of drugs for SH patients, possibly in combination with psychological treatment.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Newer generation antidepressants (nomifensine, mianserin, paroxetine) compared to placebo for adults who engage in SH.
Patient or population: adults who engage in SH
Settings: outpatient
Intervention: NGAs (nomifensine, mianserin, paroxetine)
Comparison: placebo
Outcomes Illustrative comparative risks*
(95% CI)
Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo NGAs
Repetition of SH at last
follow-up
Study population OR 0.76
(0.42 to 1.36)
243
(3 studies)
⊕⊕©©
low1,2
Quality was downgraded
owing to serious risk of
bias. Quality was further
downgraded owing to se-
rious imprecision
375 per 1000 313 per 1000
(201 to 449)
*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; NGA: newer generation antidepressant; OR: odds ratio; SH: self-harm.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Risk of bias was rated as SERIOUS as blinding of participants and blinding of outcome assessors was unclear leading to possible
performance bias and detection bias.
2 Imprecision was rated as SERIOUS as the overall sample size for each trial is small.
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B A C K G R O U N D
Description of the condition
The term ‘self-harm’ is used to describe all intentional acts of self-
poisoning (e.g., overdoses) or self-injury (e.g., self-cutting), irre-
spective of degree of suicidal intent or other types of motivation
(Hawton 2003a). Thus it includes acts intended to result in death
(‘attempted suicide’), those without suicidal intent (e.g., to com-
municate distress, to temporarily reduce unpleasant feelings), and
those with mixed motivation (Hjelmeland 2002; Scoliers 2009).
The term ‘parasuicide’ was introduced by Kreitman 1969 to in-
clude the same range of behaviour. However, ‘parasuicide’ has been
used in the United States of America (USA) to refer specifically
to acts of self-harm without suicidal intent (Linehan 1991), and
the term has largely fallen into disuse in the United Kingdom
(UK) and other countries. In the fifth version of the Diagnostic
and Statistical Manual of Mental Disorders (DSM-5; American
Psychiatric Association 2013), two types of self-harmingbehaviour
are included as conditions for further study, namely “Non-Suici-
dal Self Injury” (NSSI) and “Suicidal Behavior Disorder” (SBD).
Many researchers and clinicians, however, believe this to be an ar-
tificial and somewhat misleading categorisation (Kapur 2013).We
have therefore used the approach favoured in the UK and some
other countries where all intentional self-harm is conceptualised
in a single category, namely self-harm (SH). Within this category,
suicidal intent is regarded as a dimensional rather than a categor-
ical concept. For readers more familiar with the NSSI and SBD
distinction, SH can be regarded as an umbrella term for these two
behaviours (although it should be noted that neither NSSI nor
SBD include non-fatal self-poisoning).
SH has been a growing problem in most countries over the past
40 years. In the UK it is estimated that there are now more
than 200, 000 related presentations to general hospitals per year
(Hawton 2007). In addition, SH often occurs in the commu-
nity and does not result in presentation to hospital or other clin-
ical services (Borges 2011). SH consumes considerable hospital
resources in both high income countries (Gibbs 2004; Claassen
2006; Schmidtke 1996; Schmidtke 2004) and low to middle
income countries (Fleischmann 2005; Kinyanda 2005; Parkar
2006). Methods of SH vary, however, between high income and
low to middle income countries. In high income countries, self-
poisoning frequently involves overdoses of analgesics and psy-
chotropic drugs (Hawton 2003a; Värnik 2004; Gjelsvik 2012). In
low to middle income countries, pesticides are often consumed,
particularly in rural areas (Eddleston 2000; Gunnell 2003). Self-
cutting and other forms of self-mutilation are probably the most
common forms of non-fatal self-injury in both high and low to
middle income countries. However, fatal self-injury in high in-
come countries most commonly involves hanging and firearms
(World Health Organization 2014), whereas in some low to mid-
dle income countries, self-immolation is not uncommon (Ahmadi
2007).
In most countries, SH (unlike suicide) occurs more commonly in
females than males. However, the gender difference decreases over
the life cycle (Hawton 2008), and in some countries the difference
between the genders may have decreased in recent years (Perry
2012). SHpredominantly occurs in youngpeople, with 60-70%of
individuals in many studies being aged under 35 years. In females,
rates tend to be particularly high among 15-24 year olds, whereas
in males the highest rates are usually among those in their late 20s
and early 30s. SH is less common in older people, but then tends
to be associated with high suicidal intent (Hawton 2008), with
consequent greater risk of suicide (Murphy 2012).
Many people who engage in SH are facing acute life problems,
often in the context of longer-term difficulties (Hawton 2003b).
Common problems include disrupted relationships, employment
issues, financial and housing trouble, and social isolation. In older
people, physical health problems, bereavement, and threatened
loss of independence become increasingly important. Alcohol
abuse and, to a lesser extent, drug misuse are often present. There
may be a history of physical and/or sexual abuse and other adverse
experiences.
Both psychological and biological factors appear to increase vul-
nerability to SH. Many patients who present to hospital following
SH have psychiatric disorders, especially depression, anxiety and
substance misuse (Hawton 2013); these disorders frequently oc-
cur in combination with a personality disorder (Haw 2001). Bio-
logical factors include disturbances in the serotonergic and stress-
response systems (van Heeringen 2014).
SH is often repeated, with 15-25% of individuals who present to
hospital with SH returning to the same hospital following a repeat
episode within a year (Owens 2002; Carroll 2014). Studies from
Asia suggest a lower risk of repetition (Carroll 2014), although
there may be other repeat episodes that result in presentation to
another hospital, or do not result in hospital presentation at all.
Repetition is more common in individuals who have a history
of previous SH, personality disorder, psychiatric treatment, and
alcohol or drug misuse (Larkin 2014).
The risk of death by suicide within one year amongst people who
present to hospital with SH varies across studies from nearly 1% to
over 3% (Owens 2002; Carroll 2014). This variation reflects the
characteristics of the SH population and the background national
suicide rate. In theUK, during the first year after an SHepisode the
risk is 50-100 times that of the general population (Hawton 1988;
Hawton 2003b; Cooper 2005).Of people who die by suicide, over
half will have a history of SH (Foster 1997) and at least 15% will
have presented to hospital with SH in the preceding year (Gairin
2003). A history of SH is the strongest risk factor for suicide across
a range of psychiatric disorders (Sakinofsky 2000), and repetition
of SH further increases the risk of suicide (Zahl 2004).
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Description of the intervention
Given the high prevalence of depression in patients who engage
in SH, antidepressants are often used in treatment in the same
dose range as is generally used to treat depression. However, owing
to the increased risk of overdose in this population, including
the likelihood that patients who engage in self-poisoning may
use their own medication, antidepressants associated with lower
case fatality indices (e.g., selective serotonin reuptake inhibitors
(SSRIs); Hawton 2010) will generally be preferred.
In patients with a history of repetition of SH, especially those with
a diagnosis of borderline personality disorder (BPD), treatment
with antipsychotics may be used, although there is little evidence
for their efficacy in reducing suicidal behaviour (Stoffers 2010).
Attention has also focused on the potential efficacy of mood sta-
bilisers for this population, including both antiepileptic medica-
tions and lithium, given the high prevalence of recurrent mood
disorders in people who engage in SH. There is currently little ev-
idence that antiepileptics reduce risk of suicidal behaviour; how-
ever, there is accumulating evidence that lithium has specific anti-
suicidal effects, including reducing both the risk of SH and suicide
in patients with affective disorders (Cipriani 2013a).
The high prevalence of anxiety disorders in this population
(Hawton 2013) also suggests that other pharmacological agents,
such as benzodiazepines and other sedatives, might be expected to
have an important role in treatment. However, benzodiazepines
may increase the risk of repetition of SH (Verkes 2000). There-
fore it is usually recommended that benzodiazepines are used very
cautiously, if at all, in people at risk of SH (Verkes 2000).
There is also interest in the use of natural products (e.g., dietary
supplementation of omega-3 fatty acids) to treat a variety of men-
tal disorders, including suicidal behaviour, but there is little con-
vincing evidence of their efficacy at present (Ross 2007).
How the intervention might work
Antidepressants
Antidepressants in general would be expected to improve mood in
individuals with depression and, hence, decrease thoughts and acts
of SH. Antidepressant medications can be divided into tricyclics
and newer generation antidepressants (e.g., SSRIs). Tricyclic an-
tidepressants primarily inhibit both serotonin and norepinephrine
reuptake, whereas SSRIs specifically target synaptic serotonergic
reuptake (Feighner 1999). Given the link between serotonin ac-
tivity, impulsivity, and suicidal behaviour (van Heeringen 2014),
both tricyclic and SSRI antidepressants may be associated with a
serotonin-mediated reduction in impulsivity and enhanced emo-
tion regulation which might possibly reduce the likelihood that
an individual will engage in SH.
Antipsychotics
One risk factor for SH, including repetition of the behaviour, may
be heightened arousal, especially in relation to stressful life events.
Rationale for the use of antipsychotics is that by reducing this
arousal, the urge to engage in SH may be reduced. Lower doses
might be used to obtain this effect than are used in the treatment
of psychotic disorders (Battaglia 1999).
Mood stabilisers (including antiepileptics)
Mood stabilisers have specific benefits for patients with bipolar
disorder or unipolar depression, especially in terms of preventing
recurrence of episodes of mood disorder (Geddes 2004; Cipriani
2013b). It might therefore be anticipated that these drugs would
have benefits in terms of reducing the risk of suicidal behaviour,
although currently such an effect has only been shown for lithium
(Cipriani 2013a). Lithium may reduce the risk of suicidal be-
haviour via a serotonin-mediated reduction in impulsivity and ag-
gression. It is also possible that the long-term clinical monitoring
that all patients prescribed lithium treatment must undergo might
contribute to a reduction in SH (Cipriani 2013a).
Other pharmacological agents
Benzodiazepinesmight be anticipated to reduce suicidal behaviour
through their specific effects on anxiety (Tyrer 2012). However,
because of their GABAminergic effects, benzodiazepines may also
increase aggression and disinhibition (Albrecht 2014), which may
increase the risk of suicidal behaviour. Other pharmacological
agents, particularly the N-Methyl-D-aspartate receptor antago-
nist ketamine, may also have beneficial effects on suicidal ideation
in patients with major depression. However, it is presently un-
clear whether ketamine has a specific antisuicidal effect, or rather,
whether its effectiveness is due to a reduction in general depressive
symptomatology (Fond 2014).
Natural products
The main focus with regard to natural products and suicidal be-
haviour has been on dietary supplementation of omega-3 fatty
acids (fish oils; Tanskanen 2001). Omega-3 fatty acids have been
implicated in the neural network shown to correlate with the
lethality of recent suicidal behaviour (Mann 2013). Blood plasma
polyunsaturated fatty acid levels have also been implicated in the
serotonin-mediated link between low cholesterol and suicidal be-
haviour, suggesting that low omega-3 fatty acid levels may have a
negative impact on serotonin function (Sublette 2006). Omega-3
supplementation, in contrast, might stimulate serotonin activity,
thereby reducing the likelihood that an individual will engage in
impulsive behaviours, such as SH (Brunner 2002).
6Pharmacological interventions for self-harm in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Why it is important to do this review
SH is a major social and healthcare problem. It represents sig-
nificant morbidity, is often repeated, and has strong links to sui-
cide. It also leads to substantial healthcare costs (Sinclair 2011).
Many countries now have suicide prevention strategies (World
Health Organization 2014), all of which include a focus on im-
proved management of patients presenting with SH because of
their greatly elevated suicide risk, and also because of their high
levels of psychopathology and distress. The National Suicide Pre-
vention Strategy for England (Department of Health 2012) and
the USA’s National Strategy for Suicide Prevention (Office of the
Surgeon General (US) 2012), for example, highlight SH patients
as a key high risk group to be given special attention. In recent years
there has also been considerable focus on improving the standards
of general hospital care for SH patients. In 1994 the Royal Col-
lege of Psychiatrists published consensus guidelines for such ser-
vices (Royal College of Psychiatrists 1994), and in 2004 produced
revised guidelines (Royal College of Psychiatrists 2004). While
these guidelines focus particularly on organisation of services and
assessment of patients, there is clearly a need for effective treat-
ments for SH patients; these may include pharmacological as well
as psychosocial interventions. In 2004 the National Institute for
Clinical Excellence (NICE;NCCMH2004) produced a guideline
on SH which focused on its short-term physical and psychologi-
cal management. More recently, NICE produced a second guide
with an aim towards longer-term management (NICE 2011), us-
ing some interim data from the present review as the evidence base
on therapeutic interventions. A similar guideline was produced
in Australia and New Zealand (Boyce 2003). We had previously
conducted a systematic review of treatment interventions for SH
patients, in terms of reducing repetition of SH, which highlighted
the paucity of evidence for effective treatments, at least in terms
of this outcome (Hawton 1998; Hawton 1999); the first NICE
guideline essentially reinforced this conclusion (NCCMH 2004).
Using interim data from the present review, the second NICE
guideline concluded that there was evidence showing clinical ben-
efit of brief psychological interventions in reducing repetition of
SH, compared with routine care (NICE 2011). However, there
was no evidence of similar beneficial effects for pharmacological
treatments.
We have now fully updated our original review in order to provide
contemporary evidence to guide clinical policy and practice. We
have also divided the review into three reviews: the present review
which focuses on pharmacological interventions for adults, a sec-
ond review on psychosocial interventions for adults, and the third
on interventions for children and adolescents. In the earlier review
we focused on repetition of SH and suicide as the main outcomes.
In this update, we have now also included data on treatment ad-
herence, depression, hopelessness, suicidal ideation, and problem-
solving.
O B J E C T I V E S
To identify all randomised controlled trials (RCTs) on pharmaco-
logical agents or natural products for SH in adults, and to conduct
meta-analyses (where possible) to compare the effects of specific
treatments with comparison types of treatment (e.g., placebo or
alternative pharmacological treatment) for SH patients.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials, including cluster ran-
domised and cross-over trials, of specific pharmacological agents
or natural products versus placebo or any other pharmacological
comparisons in the treatment of adult SH patients.
Types of participants
Participant characteristics
Participants were adult males and females (age 18 and over) of all
ethnicities. We also included trials where there were a small mi-
nority (<15%) of adolescent participants. However, we undertook
sensitivity analyses to assess the effect of inclusion of such trials.
Diagnosis
Participants who had engaged in any type of non-fatal intentional
self-poisoning or self-injury in the six months prior to trial entry
resulting in presentation to clinical services were included. There
were no restrictions on the frequency with which patients engaged
in SH; thus, for example, we included trials where participants had
frequently repeated SH (e.g., those with self-harming behaviour
as part of borderline personality disorder).
We defined SH as any non-fatal intentional act of self-poisoning
or self-injury, irrespective of degree of suicidal intent or other types
of motivation. Thus it includes acts intended to result in death
(“attempted suicide”), those without suicidal intent (e.g., to com-
municate distress, to temporarily reduce unpleasant feelings), and
those with mixed motivation. Self-poisoning includes both over-
doses of medicinal drugs and ingestion of substances not intended
for consumption (e.g., pesticides). Self-injury includes acts such
as self-cutting, self-mutilation, attempted hanging, and jumping
in front of moving vehicles. We only included trials where partic-
ipants presented to clinical services as a result of SH.
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Co-morbidities
There were no restrictions in terms of whether or not patients
had psychiatric disorders, or the nature of those disorders, with
the exception of intellectual disability, where any SH behaviour is
likely to be repetitive (e.g., head banging) as the purpose of this
behaviour is usually different from that involved in SH.The reader
is instead referred to a recent Cochrane review of pharmacological
interventions for self-injury in this population (Rana 2013).
Setting
Interventions delivered in inpatient or outpatient settings were
eligible for inclusion, as were trials from any country.
Subset data
We did not include trials in which only some participants had en-
gaged in SH or trials of people with psychiatric disorders in which
SHwas an outcome variable but was not an inclusion criterion for
entry into the trial.
Types of interventions
Experimental interventions
These included:
1. Tricyclic antidepressants (TADs; e.g., amitriptyline);
2. Newer generation antidepressants (NGAs), including SSRIs
(e.g., fluoxetine), serotonin and noradrenaline reuptake
inhibitors (SNRIs; e.g., venlafaxine), norepinephrine reuptake
inhibitors (NRIs; e.g., reboxetine), tetracyclic antidepressants
(TAs; e.g., maprotiline), noradrenergic specific serotonergic
antidepressants (NaSSAs; e.g., mirtazapine), serotonin antagonist
or reuptake inhibitors (SARIs; e.g., trazodone), or reversible
inhibitors of monoamine oxidase type A (RIMAs; e.g.,
moclobemide);
3. Any other antidepressants such as irreversible mono-amine
oxidase inhibitors (MAOIs; e.g., bupropion);
4. Antipsychotics (e.g., olanzapine);
5. Mood stabilisers, including antiepileptics (e.g., sodium
valporate) and lithium;
6. Other pharmacological agents (e.g., benzodiazepines,
ketamine);
7. Natural products (e.g., omega-3 essential fatty acid
supplementation).
Comparator interventions
While treatment as usual (TAU), which usually refers to routine
clinical service provision, is often used as a comparator in trials
of psychosocial interventions, it is not generally used in pharma-
cological trials, where comparison with the specific effects of an
active drug is being made. For the purposes of the current review,
then, the comparator was placebo, which consisted of any phar-
macologically inactive treatment such as sugar pills or injections
with saline, or another comparator pharmacological intervention
(e.g., another standard pharmacological agent, or reduced dose of
the intervention agent).
Combination interventions
We also planned to include combination interventions where any
pharmacological agent of any class as outlined above is combined
with psychological therapy. However, as the focus of this review
is the effectiveness of pharmacological agents for SH patients,
we only included such trials if both the intervention and control
groups received the same psychological therapy to ensure that any
potential effect of the psychosocial therapy was balanced across
both groups. The effectiveness of psychosocial therapy in adults is
the subject of a separate review.
Types of outcome measures
Primary outcomes
The primary outcomemeasure in this reviewwas the occurrence of
repeated SH (defined above) over a maximum follow-up period of
two years. Repetition was identified through self-report, collateral
report, clinical records, or research monitoring systems. As we
wished to incorporate themaximal amount of data from each trial,
we included both self-reported and hospital records of SH where
available. We also assessed frequency of repetition of SH at final
follow-up.
Secondary outcomes
1. Treatment adherence
Thiswas assessed using a range ofmeasures of adherence, including
pill counts, changes in blood measures, and the proportion of
participants that both started and completed treatment.
2. Depression
This was assessed either continuously, as scores on psychometric
measures of depression symptoms (for example total scores on
Beck Depression Inventory (BDI; Beck 1961) or scores on the
depression sub-scale of the Hospital Anxiety and Depression Scale
(HADS; Zigmond 1983)), or dichotomously, as the proportion
of patients reaching defined diagnostic criteria for depression.
3. Hopelessness
This was assessed by scores on psychometric measures of hope-
lessness, for example, total scores on the Beck Hopelessness Scale
(BHS; Beck 1974).
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4. Suicidal ideation
This was assessed either continuously, as scores on psychometric
measures of suicidal ideation (for example total scores on the Beck
Scale for Suicidal Ideation (BSS; Beck 1988)), or dichotomously, as
the proportion of patients reaching a defined cut-off for ideation.
5. Problem-solving
This was assessed either continuously, as scores on a psychiatric
measure of problem-solving ability (for example total scores on
the Problem Solving Inventory (PSI; Heppner 1988)), or dichoto-
mously, as the proportion of patients with improved problems.
6. Suicide
This included both register-recorded deaths and reports from col-
lateral informants such as family members or neighbours.
Timing of outcome assessment
We reported outcomes for the following time periods:
1. During treatment.
2. At the conclusion of the treatment period.
3. Between zero and six months after the conclusion of the
treatment period.
4. Between six and 12 months after the conclusion of the
treatment period.
5. Between 12 and 24 months after the conclusion of the
treatment period.
Hierarchy of outcome assessment
Where a trial measured the same outcome (e.g., depression) in two
or more ways, we used the most common measure across trials
in any meta-analysis, but we also reported scores from the other
measure in the text of the review.
Search methods for identification of studies
Electronic searches
1. The Cochrane Depression, Anxiety and Neurosis Review
Group’s Specialised Register (CCDANCTR)
The Cochrane Depression, Anxiety and Neurosis Group (CC-
DAN) maintains two clinical trials registers at their editorial base
in Bristol, UK: a references register and a studies-based register.
The CCDANCTR-References register contains over 37,500 re-
ports of randomised controlled trials on depression, anxiety and
neurosis. Approximately 60% of these references have been tagged
to individual, coded trials. The coded trials are held in the CC-
DANCTR-Studies register and records are linked between the two
registers through the use of unique study ID tags. Coding of trials
is based on the EU-Psi codingmanual. Please contact theCCDAN
Trials Search Coordinator for further details.
Reports of trials for inclusion in the group’s registers are collated
from weekly generic searches of MEDLINE (1950 to date), EM-
BASE (1974 to date), and PsycINFO (1967 to date), as well as
quarterly searches of the Cochrane Central Register of Controlled
Trials (CENTRAL).
The CCDANCTR (Studies and References) was searched on 2
September 2014 using terms for self-harm (condition only), as
outlined in Appendix 1.
No restrictions on date, language, or publication status were ap-
plied to the search.
2. Additional electronic database searches
Complementary searches of MEDLINE (1998 to 2013), EM-
BASE (1998 to 2013), PsycINFO (1998 to 2013), and CEN-
TRAL (The Cochrane Library, 1998 to 2013) were conducted
by Sarah Stockton, librarian at the University of Oxford, fol-
lowing the search strategy outlined in Appendix 2. Additionally,
KW searched the Australian Suicide Prevention RCT Database
(Christensen 2014). KW also conducted electronic searches of
ClinicalTrials.gov and the ISRCTN registry using the keywords
random*AND suicide attempt*OR self$harm* to identify relevant
ongoing trials.
Both the original version of this review and an unpublished version
also incorporated searches of SIGLE (1980 to March 2005) and
SocioFile (1963-July 2006).
Searching other resources
Hand searching
For the original version of this review, the authors hand searched
ten specialty journals within the fields of psychology and psychi-
atry, including all English language suicidology journals, as out-
lined in Appendix 3. As these journals are now indexed in major
electronic databases, hand searching was not repeated for this up-
date.
Reference lists
The reference lists of all relevant papers known to the investigators
were checked, as were the reference lists of major reviews which
include a focus on interventions for SH patients (Baldessarini
2003; Baldessarini 2006; Beasley 1991; Brausch 2012; Burns
2000; Cipriani 2005; Cipriani 2013a; Comtois 2006; Crawford
2007a; Crawford 2007b; Daigle 2011; Daniel 2009; Dew 1987;
Gould 2003; Gray 2001; Gunnell 1994; Hawton 1998; Hawton
1999; Hawton 2012; Hennen 2005; Hepp 2004; Hirsch 1982;
Kapur 2010; Kliem 2010; Lester 1994; Links 2003; Lorillard
2011a; Lorillard 2011b; Luxton 2013; Mann 2005; McMain
2007; Milner 2015; Möller 1989; Möller, 1992; Montgomery
9Pharmacological interventions for self-harm in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1995; Muehlenkamp 2006; Müller-Oerlinghausen 2005; Nock
2007; Ougrin 2011; Ougrin 2015; Smith 2005; Stoffers 2010;
Tarrier 2008; Tondo 1997; Tondo 2000; Tondo 2001; Townsend
2001; van der Sande 1997).
Correspondence
The authors of trials and other experts in the field of suicidal be-
haviour were consulted to find out if they were aware of any ongo-
ing or unpublished RCTs concerning the use of pharmacological
interventions for adult SH patients.
Data collection and analysis
For details of the data collection and analysis methods used in the
original version of this review see Appendix 4.
Selection of studies
For this update of the review, all authors independently assessed
the titles of trials identified by the systematic search for eligibility.
A distinction was made between:
1. Eligible trials, in which any psychopharmacological
treatment was compared with a control (e.g., placebo medication
or comparator drug/dose).
2. General treatment trials (without any control treatment).
All trials identified as potentially eligible for inclusion then un-
derwent a second screening. Pairs of review authors, working in-
dependently from one another, screened the full text of relevant
trials to identify whether the trial met our inclusion criteria.
Disagreements were resolved following consultation with KH.
Where disagreements could not be resolved from the information
reported within the trial, or where it was unclear whether the trial
satisfied our inclusion criteria, study authors were contacted to
provide additional clarification.
Data extraction and management
In the current update, data from included trials was extracted by
KW and one of either TTS, EA, DG, PH, ET, or KvH using a
standardised extraction form. Review authors extracted data inde-
pendently of one another. Where there were any disagreements,
these were resolved through consensus discussions with KH.
Data extracted from each eligible trial concerned participant de-
mographics, details of the treatment and control interventions,
and information on the outcome measures used to evaluate the
efficacy of the intervention. Study authors were contacted to pro-
vide raw data for outcomes that were not reported in the full text
of included trials.
Both dichotomous and continuous outcome data were extracted
from eligible trials. As the use of non-validated psychometric scales
is associated with bias, we extracted continuous data only if the
psychometric scale used to measure the outcome of interest had
been previously published in a peer-reviewed journal (Marshall
2000), and was not subjected to item, scoring, or other modifica-
tion by the trial authors.
We planned the following main comparisons.
1. Tricyclic antidepressants versus placebo.
2. Tricyclic antidepressants versus another comparator drug/
dose.
3. Newer generation antidepressants versus placebo.
4. Newer generation antidepressants versus another
comparator drug/dose.
5. Any other antidepressants versus placebo.
6. Any other antidepressants versus another comparator drug/
dose.
7. Antipsychotics versus placebo.
8. Antipsychotics versus another comparator drug/dose.
9. Mood stabilisers versus placebo.
10. Mood stabilisers versus another comparator drug/dose.
11. Other pharmacological agents versus placebo.
12. Other pharmacological agents versus another comparator
drug/dose.
13. Natural products versus placebo.
14. Natural products versus another comparator drug/dose.
Assessment of risk of bias in included studies
Given that highly biased trials aremore likely to overestimate treat-
ment effectiveness (Moher 1998), the quality of included trials was
evaluated independently by KW and one of either TTS, EA, DG,
PH, ET, or KvH using the criteria described in Higgins 2008a.
This tool encourages consideration of the following domains:
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
Each study was judged as being at “low”, “high”, or “unclear” risk
of each potential bias, and a supporting quotation from the trial
report was incorporated to justify this judgment. Where inade-
quate details of the randomisation, blinding, or outcome assess-
ment procedureswere provided in the original report, we contacted
authors to provide clarification. Disagreements were resolved fol-
lowing discussion with KH. Risk of bias for each included trial is
reported in the text of the review.
Measures of treatment effect
Dichotomous outcomes
We summarised dichotomous outcomes, such as the number of
participants engaging in a repeat SH episode and the number of
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deaths by suicide, using summary odds ratios (OR) and the ac-
companying 95% confidence interval (CI), as OR is the most ap-
propriate effect size statistic for summarising associations between
two dichotomous groups (Fleiss 1994).
Continuous outcomes
For outcomes measured on a continuous scale, we used mean
differences (MD) and accompanying 95% CI where the same
outcome measure was employed. In future updates of this review,
if different scales are used to assess a given outcome, we will use
the standardised mean difference (SMD) and its accompanying
95% CI.
Trials were aggregated for the purposes of meta-analysis only if
treatments were sufficiently similar. For trials that could not be
included in a meta-analysis, we have instead provided narrative
descriptions of the results.
Unit of analysis issues
Zelen design trials
Trials in this area are increasingly employing Zelen’s method in
which consent is obtained subsequent to randomisation and treat-
ment allocation. This design may lead to bias if, for example, par-
ticipants allocated to one particular arm of the trial disproportion-
ally refuse to provide consent for participation or, alternatively, if
participants only provide consent if they are allowed to cross-over
to the other treatment arm (Torgerson 2004). No trial included in
this review used Zelen’s design. Given the uncertainty of whether
to use data for the primary outcome based on all those randomised
to the trial, or only those who consent to participation, should a
trial using Zelen’s method be identified in future updates of this
review we plan to extract data using both sources where possible.
We also plan to conduct sensitivity analyses to investigate what
impact, if any, the inclusion of these trials may have on the pooled
estimate of treatment effectiveness.
Cluster randomised trials
Cluster randomisation, for example by clinician or general prac-
tice, can lead to overestimation of the significance of a treatment
effect, resulting in an inflation of the nominal type I error rate,
unless appropriate adjustment is made for the effects of clustering
(Donner 2002; Kerry 1998). Although no trials identified by this
review used cluster randomisation methods, should any future tri-
als in this area use this design we will follow the guidance outlined
in Higgins 2008b, section 16.3.4.
Cross-over trials
A primary concern with cross-over trials is the “carry-over” effect
in which the effect of the intervention treatment (e.g., pharma-
cological, physiological, or psychological) influences the partic-
ipant’s response to the subsequent control condition (Elbourne
2002). As a consequence, on entry to the second phase of the trial,
participants may differ systematically from their initial state de-
spite a wash-out phase. This, in turn, may result in a concomitant
underestimation of the effectiveness of the treatment intervention
(Curtin 2002a; Curtin 2002b). Once again, no trials included in
the current review used cross-over methodology. However, should
we identify any such trials in future updates, only data from the
first phase of the trial, prior to cross-over, will be extracted to pro-
tect against the carry-over effect.
Studies with multiple treatment groups
One trial in the current review includedmultiple treatment groups
(Hirsch 1982). As both intervention arms in this trial investigated
the effectiveness of a newer generation antidepressant, we com-
bined dichotomous data from these two arms and compared the
combined data with data from the placebo arm. For outcomes re-
ported on a continuous scale, we combined data using the formula
given in Higgins 2008c, section 7.7.3.8.
Studies with adjusted effect sizes
None of the trials included in the current update provided adjusted
effect sizes. In future updates of this review, however, where trials
report both unadjusted and adjusted effect sizes, we will include
only unadjusted effect sizes.
Dealing with missing data
We as review authors did not imputemissing data as we considered
that the bias that would be introduced by doing this would have
outweighed any benefit (in terms of increased statistical power)
that may have been gained by the inclusion of imputed data. How-
ever, where authors omitted standard deviations (SD) for contin-
uous measures, these were estimated using the method described
in Townsend 2001.
Dichotomous data
Although many authors conducted their own intention-to-treat
analyses, none presented intention-to-treat analyses as defined by
Higgins 2008b. Therefore, outcome analyses for both dichoto-
mous and continuous data were based on all information avail-
able on trial participants. For dichotomous outcomes, we included
data on only those participants whose results were known, using
as the denominator the total number of participants with data for
the particular outcome of interest at follow-up, as recommended
(Higgins 2008b).
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Continuous data
For continuous outcomes, we have included data only on observed
cases.
Missing data
Where data on outcomes of interest were incomplete or were ex-
cluded from the text of the trial, study authors were contacted in
order to try to obtain further information.
Assessment of heterogeneity
Between-study heterogeneity can be assessed using either the Chi2
or I2 statistics. In this review, however, we used only the I2 statistic
to determine heterogeneity as this is considered to be more reli-
able (Higgins 2003). The I2 statistic indicates the percentage of
between-study variation due to chance (Higgins 2003), and can
take any value from 0% to 100%. We used the following values to
denote unimportant, moderate, substantial, and considerable het-
erogeneity, respectively: 0% to 40%, 30% to 60%, 50% to 90%,
and 75% to 100% as per the guidance in the Cochrane Handbook
(Deeks 2008).Where we found substantial levels of heterogeneity
(i.e., ≥ 75%), reasons for this heterogeneity were explored. We
also planned to investigate heterogeneity when the I2 statistic was
lower than 75% where either the direction or magnitude of a trial
effect size was clearly discrepant from that of other trials included
in the meta-analysis (see Subgroup analysis and investigation of
heterogeneity section for further information on these analyses).
Assessment of reporting biases
Reporting bias occurs when the decision to publish a particu-
lar trial is influenced by the direction and significance of its re-
sults (Egger 1997). Research suggests, for example, that trials with
statistically significant findings are more likely to be submitted
for publication and to subsequently be accepted for publication
(Hopewell 2009), leading to possible overestimation of the true
treatment effect. To assess whether trials included in any meta-
analysis were affected by reporting bias, we entered their data into
a funnel plot but only, as recommended, when a meta-analysis in-
cluded results from at least ten trials. Where evidence of any small-
study effects were identified, reasons for funnel plot asymmetry,
including the presence of publication bias, were explored (Egger
1997).
Data synthesis
For the purposes of meta-analysis, we calculated the pooled OR
and accompanying 95% CI using the random-effects model as
this is the most appropriate model for incorporating heterogene-
ity between trials (Deeks 2008, section 9.5.4). Specifically, for di-
chotomous data, theMantel-Haenszel methodwas used whilst the
inverted variance method was used for continuous data. However,
a fixed-effect analysis was also undertaken to investigate the poten-
tial effect of method choice on the estimates of treatment effect.
Any material differences in ORs between these two methods are
reported descriptively in the text of the review. All analyses were
undertaken in RevMan, version 5.3.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses
In the original version of this review, we had planned to under-
take subgroup analyses by repeater status and gender but found
there were insufficient data. Consequently, in this update we only
undertook a priori subgroup analyses by gender or repeater status
where there were sufficient data to do so.
Investigation of heterogeneity
Although no meta-analysis was associated with substantial levels
of between-study heterogeneity (i.e., I2 ≥75%) in this review,
in future updates, should this be the case KH and KW would
independently triple-check the data to ensure it had been correctly
entered. Assumingdata have been entered correctly, wewould then
investigate the source of this heterogeneity by visually inspecting
the forest plot and removing each trial which had a very different
result to the general pattern of the others until homogeneity was
restored as indicted by an I2 statistic <75%. We would report the
results of this sensitivity analysis in the text of the review alongside
hypotheses regarding the likely causes of the heterogeneity.
Sensitivity analysis
We undertook sensitivity analyses, where appropriate, as outlined
below:
1. Where a trial or trials made use of Zelen’s method of
randomisation (see Unit of analysis issues section).
2. Where a trial or trials contributed substantial levels of
between-study heterogeneity (see Subgroup analysis and
investigation of heterogeneity section).
3. Where a trial or trials included a mixture of both adolescent
and adult participants.
4. Where a trial or trials specifically recruited individuals
diagnosed with borderline personality disorder.
’Summary of findings’ tables
A ’Summary of findings’ table was prepared for the primary out-
comemeasure, repetition of SH, following recommendations out-
lined in Schünemann 2008a, section 11.5. This table provides in-
formation concerning the overall quality of evidence from each
included trial. The ’Summary of findings’ table was prepared us-
ing GRADEpro software (GRADEpro). Quality of the evidence
was assessed following recommendations in Schünemann 2008b,
section 12.2.
12Pharmacological interventions for self-harm in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E S U L T S
Description of studies
Results of the search
For this update, a total of 23,725 citations were found using the
search strategy outlined in Appendix 1 and Appendix 2. A further
10 were identified through correspondence and discussion with
researchers in the field; these trials were ongoing at the time of
the systematic search. All but one have subsequently been pub-
lished and a report on the remaining trial is currently in prepa-
ration. We were able to include data for this trial, however, by
correspondence with and permission from study authors. In con-
sultation with CCDAN, we have since divided the original review
into three separate reviews: the present review which focuses on
pharmacological interventions for adults, a second review on psy-
chosocial interventions for adults, and the third on interventions
for children and adolescents. As these 10 trials evaluated psychoso-
cial rather than pharmacological interventions, they are included
in the related two reviews.
After deduplication, the initial number was reduced to 16,700. Of
these, 16,459 were excluded after screening, whilst a further 217
were excluded after reviewing the full texts (Figure 1).
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Figure 1. Search flow diagram of included and excluded trials.
14Pharmacological interventions for self-harm in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
In the previous versions of this review (Hawton 1998; Hawton
1999; NICE 2011), seven trials of pharmacological interventions
for SH patients were included. The present update failed to locate
any additional trials of pharmacological agents. The present review
therefore includes seven non-overlapping trials (Battaglia 1999;
Hallahan 2007; Hirsch 1982; Lauterbach 2008; Montgomery
1979; Montgomery 1983; Verkes 1998). No further reports pro-
vided additional information on these trials.
Two of the trials have not been published (Montgomery 1979;
Hirsch 1982).Unpublisheddatawere obtained from study authors
for three of the trials (Battaglia 1999; Hallahan 2007; Verkes
1998).
Two ongoing trials of pharmacological interventions were also
identified (see Characteristics of ongoing studies section for fur-
ther information on these trials).
Design
Of the seven trials, all were described as randomised controlled
trials. All employed a simple randomisation procedure based on
individual allocation to the intervention and control groups.
Participants
The included trials comprised a total of 546 participants. All had
engaged in at least one episode of SH in the six months prior to
randomisation.
Participant characteristics
Of the five trials that recorded information on age, the average
age of participants at randomisation was 35.3 years (SD 3.1). Two
trials included a small number of adolescent participants (i.e.,
under 18 years of age) but the precise number was not recorded
in either trial (Hallahan 2007; Hirsch 1982). Of the six trials that
reported information on gender, the majority of participants were
female (63.5%), reflecting the typical pattern for SH (Hawton
2008).
Diagnosis
A history of SH prior to the index episode (i.e., multiple episodes
of SH) was a requirement for participation in five trials (Battaglia
1999; Hallahan 2007; Lauterbach 2008; Montgomery 1979;
Montgomery 1983). In one trial, almost one-third (30.0%) of par-
ticipants had a history of multiple episodes (Verkes 1998) whilst
in the remaining trial the proportion was not reported (Hirsch
1982). Only one trial included participants who had made a “sui-
cide attempt” (i.e., with evidence of suicidal intent; Lauterbach
2008) whilst in two others, although only those who made a “sui-
cide attempt” were eligible to participate, it is unclear whether
all participants intended to die as a result (Battaglia 1999; Verkes
1998). The remaining trials did not provide any information on
intent.
Information on the methods of SH for the index episode was
not reported in five trials (Battaglia 1999; Hallahan 2007;
Montgomery 1979;Montgomery 1983;Verkes1998). In one trial,
only those participants who had engaged in self-poisoning with
either over-the-counter or prescription drugs (i.e., not illicit sub-
stances or poison) were eligible to participate (Hirsch 1982), whilst
in the remaining trial (Lauterbach 2008) a variety of methods
were used, including: self-poisoning (73.2%), self-injury (14.4%),
jumping from a height (2.5%), and attempted hanging, attempted
shooting, or attempted drowning (5.0%). The methods used by
the remaining 4.9% of participants in this trial were not reported.
Co-morbidities
Information on current psychiatric diagnoses were reported in five
trials (see Table 1). In these trials, the most common psychiatric
diagnoses were for borderline personality disorder (k = 3, mean
78.4%) and other personality disorder (k = 3, mean 52.0%). One
trial included a high proportion of participants diagnosed with
major depression (76.0%; Lauterbach 2008).
Details on comorbid diagnoses were reported in one trial (
Lauterbach 2008). For this trial, the most common comorbidity
was for any personality disorder (33.5%), followed by substance
use disorder (8.4%), and any anxiety disorder (7.2%). In a second
trial, 25.3% of the sample were diagnosed with more than one
psychiatric disorder from the following: dysthymia, any anxiety
disorder, any dissociative disorder, alcohol abuse, any adjustment
disorder, and any depressive disorder (Verkes 1998). However, the
proportion diagnosed with each comorbid condition was not pro-
vided.
Setting
Of the seven independent RCTs included in this review, three were
from the UK (Hirsch 1982; Montgomery 1979; Montgomery
1983), and one was from each of the USA (Battaglia 1999), Ger-
many (Lauterbach 2008), the Netherlands (Verkes 1998) and the
Republic of Ireland (Hallahan 2007). Although all participants
were identified following a hospital admission for SH, five trials
did not clearly specify if treatment was delivered on an inpatient
or outpatient basis. Two trials were described as being conducted
in an outpatient setting (Lauterbach 2008; Verkes 1998).
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Interventions
The trials included in this review investigated the effectiveness of
various pharmacological agents:
1. Newer generation antidepressants (mianserin, nomifensine,
paroxetine) versus placebo (Hirsch 1982; Montgomery 1983;
Verkes 1998).
2. Antipsychotics vs. placebo (Montgomery 1979).
3. Antipsychotics vs. comparator drug/dose (Battaglia 1999).
4. Mood stabilisers (lithium) vs. placebo (Lauterbach 2008).
5. Natural products (omega-3 essential fatty acid; n-3EFA) vs.
placebo (Hallahan 2007).
Outcomes
All trials reported information on the primary outcome, repeti-
tion of SH. In two trials this was based on self-reported informa-
tion (Battaglia 1999; Lauterbach 2008), and in two further trials
on re-presentation to hospital (Hallahan 2007; Hirsch 1982). For
the remaining three trials the source of information for this out-
come was unclear (Montgomery 1979;Montgomery 1983; Verkes
1998).
Treatment adherence was assessed using pill counts (Hallahan
2007; Verkes 1998). Depression was assessed using the BDI in
two trials (Hallahan 2007; Verkes 1998) or the Hamilton Depres-
sion Rating Scale (HDRS; Hamilton 1960) in two further trials
(Hallahan 2007; Lauterbach 2008). Hopelessness was assessed us-
ing the BHS (Lauterbach 2008; Verkes 1998). Suicidal ideation
was assessed using either the sub-scale of the Overt Aggression
Scale (Hallahan 2007) or the BSS (Lauterbach 2008). It was un-
clear how suicide was assessed in any of the included trials. No
trial reported information on problem-solving.
Excluded studies
A total of 217 articles were excluded from this update: 94 were
excluded because not all patients engaged in SH; 60 used a non-
randomised clinical trial design; 27 were reviews, editorials, letters
to the editor, or conference proceedings; 23were trial protocols; 11
were excluded as SH could have occurred at any point rather than
within six months of randomisation; and one each were excluded
either because only data from one trial arm were presented (how-
ever, a related publication in which data for both the intervention
and control arms were presented was eligible for inclusion), or be-
cause the data reported in the article were for a period beyond two
years (however, articles reporting data for earlier follow-up periods
for this trial were eligible for inclusion).
Details on the reasons for exclusion of 12 trials clearly related to
pharmacological interventions for suicidality can be found in the
Characteristics of excluded studies section.
Ongoing studies
Two ongoing trials of pharmacological interventions, one of oral
lithium (Liang 2014) and one of oral ketamine (Sharon 2014),
were identified. Full details of these trials are provided in the
Characteristics of ongoing studies section.
Studies awaiting classification
There were no potentially eligible trials which have not been in-
corporated into the review.
Risk of bias in included studies
Summaries of the overall risk of bias for the included trials are
presented in Figure 2 and Figure 3. Risk of bias for each included
trial is also considered within the text of the review.
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Figure 2. Risk of bias graph: Review authors’ judgements for each risk of bias item presented as percentages
across all included trials.
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Figure 3. Risk of bias summary graph: review authors’ judgements about each risk of bias item for each
included trial.
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Sequence generation
Of the seven independent trials, all used random allocation. The
majority (k = 4; 57.1%) were rated as having an unclear risk of bias
as no information on the method used to generate the random
sequence was provided. Three trials were rated as being at low risk
of bias: two used a computerised program to generate the random
sequence (Hallahan 2007; Lauterbach 2008) whilst the third used
alternate allocation of identical blister packs to randomly assign
participants to the active or placebo groups (Verkes 1998).
Allocation concealment (selection bias)
Information on allocation concealment was not provided in the
majority of trials, earning them a rating of unclear risk (k = 5;
71.4%). Two trials were rated as being at low risk of bias as the
random sequence was generated by an offsite researcher (Verkes
1998) or a third party researcher working independently from the
trial team (Hallahan 2007). For the latter trial, moreover, addi-
tional attempts weremade to prevent participants from guessing to
which treatment group they had been allocated by adding the taste
of the experimental medication to the placebo (Hallahan 2007).
Blinding (performance bias and detection bias)
Blinding was assessed separately for participants, clinical person-
nel, and outcome assessors.
Blinding of participants
Blinding of participants was classified as resulting in a low risk of
bias for all trials included in this review as participant blinding was
maintained through the use of identical capsules or blister packs
for both the active agent and placebo arms.
Blinding of personnel
The majority of trials in this review were rated as being at low risk
(k = 4; 57.1%) as personnel blinding was maintained through the
use of identical capsules or blister packs for both the active agent
and placebo arms (Battaglia 1999; Hallahan 2007; Montgomery
1983; Verkes 1998). The remaining three trials were rated as at
being at unclear risk of bias. For two, no information on personnel
blinding was provided (Hirsch 1982; Montgomery 1979). For
one trial, blinding could not be maintained in all cases due to the
occurrence of serious suicidal behaviour or insufficient treatment
adherence (Lauterbach 2008).
Blinding of outcome assessors
Four trials were rated as being at low risk of bias (Battaglia 1999;
Lauterbach 2008;Montgomery 1979;Montgomery 1983) as out-
come assessors were blind to treatment allocation. For the remain-
ing three trials (Hallahan 2007; Hirsch 1982; Verkes 1998) no in-
formation on blinding of outcome assessors was provided. These
three trials were therefore rated as being at unclear risk of bias for
this item.
Incomplete outcome data (attrition bias)
Three trials reported conducting analyses on an intention-to-treat
basis. Two did not report any further details on the method used
to conduct intention-to-treat analyses (Lauterbach 2008; Verkes
1998) but as all participantswere included in the analyses, these tri-
als were nonetheless classified as being at low risk.One used the last
observation carried forward method (Hallahan 2007), which we
understandmay introduce bias (Engles 2003), and sowas classified
as being at unclear risk of bias for this item. A further trial was rated
as being at unclear risk of bias for this item as no details on incom-
plete outcome reporting were provided (Hirsch 1982). Three tri-
als used per protocol analyses (Battaglia 1999; Montgomery 1979;
Montgomery 1983). As there was a greater than 0% drop-out rate
for these three trials, all were rated as having high risk of bias for
this item.
Selective reporting (reporting bias)
As the review authors did not have access to trial protocols for the
trials included in this review, it is difficult to assess the degree to
which selective outcome reporting could have occurred. Conse-
quently the majority of trials were classified as being at unclear
risk for this item (k = 5; 71.4%). For two trials, numerical data for
non-significant outcomes were not reported (Hirsch 1982; Verkes
1998).These trials were therefore rated as at being at high risk of
bias for this item.
Other potential sources of bias
For one trial, significant imbalances between the active andplacebo
arms in terms of history ofmultiple “suicide attempts”, personality
disorder diagnosis, and scores on the Suicide Intent Scale for the
index attemptwere apparent (Lauterbach 2008). As in all cases this
imbalance was suggestive of worse prognosis for the intervention
group, this trial was rated as being at high risk of bias for this item.
The remaining six trials were classified as having low risk of bias
for this item as no additional sources of bias were apparent.
Few trials used systematic means to investigate whether partici-
pants were able to guess if they had been allocated to the active or
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placebo arm. Only one (Hallahan 2007) questioned participants
at the conclusion of the trial, however, this information was not
presented in the trial report.
The source of funding was not indicated in three trials (Hirsch
1982; Montgomery 1979; Montgomery 1983). In two, funding
was jointly received from a pharmaceutical company and a gov-
ernment department (Lauterbach 2008; Verkes 1998), in a further
trial funding was received from both government and university
sources (Battaglia 1999), and for the remaining trial, funding was
exclusively received from a university source (Hallahan 2007).
Effects of interventions
See: Summary of findings for the main comparison Newer
generation antidepressants versus placebo; Summary of findings
2 Antipsychotics versus placebo or another comparator drug/
dose; Summary of findings 3 Mood stabilisers versus placebo;
Summary of findings 4 Natural products versus placebo
As only newer generation antidepressants were evaluated against
placebo in more than one non-overlapping trial, meta-analyses
were only undertaken for this intervention.
Although antipsychotics were also evaluated in more than one in-
dependent trial, one used placebo as the comparator (Montgomery
1979) whilst the second used the intervention antipsychotic in an
ultra-low dosage as the comparator (Battaglia 1999).We therefore
think it is inappropriate to pool these trials and have therefore
analysed them separately. All other drug classes, which were eval-
uated in only single trials, are reported in the text.
There were no trials of tricyclic antidepressants, other antidepres-
sants (e.g., MAOIs), antiepileptics, nor of other pharmacological
agents (e.g., benzodiazepines, ketamine).
Comparison 1: newer generation antidepressants
versus placebo
Three trials evaluated the effectiveness of different newer genera-
tion antidepressants (NGAs) in patients admitted to general hos-
pital facilities following either self-poisoning or attempted suicide.
The first compared 30-60 mg mianserin or 75-150 mg nomifen-
sine against placebo (N = 114; Hirsch 1982), the second compared
30 mg mianserin against placebo (N = 58; Montgomery 1983),
whilst the third compared 40 mg paroxetine per day plus weekly/
fortnightly supportive psychotherapy to placebo and supportive
psychotherapy (N = 91; Verkes 1998). We acknowledge that these
antidepressants are from different drug classes (heterocyclic, SSRI,
and NDRI respectively); however, we have combined results for
these agents into one comparison in order to address the question
of whether antidepressant treatment using NGAsmight be of gen-
eral benefit in this patient population. We have also sub-grouped
the individual drugs in a post hoc analysis.
Primary outcome
1.1 Repetition of SH
There was no evidence of a significant treatment effect for mi-
anserin or nomifensine at 12 weeks (15/76 versus 6/38; OR 1.31,
95% CI 0.46 to 3.71; k = 1; N = 114; Hirsch 1982) or for mi-
anserin at six months (8/17 versus 12/21; OR 0.67, 95% CI 0.18
to 2.41; k = 1; N = 38; Montgomery 1983). In the trial involving
paroxetine with adjunct psychotherapy, furthermore, there was
also no evidence of a significant treatment effect at 12 months
(15/46 versus 21/45; 95% OR 0.55, 0.24 to 1.29; k = 1; N = 91;
Verkes 1998).
A post hoc analysis was performed to assess repetition for all three
trials at the last follow-up (i.e., 12weeks (Hirsch 1982), sixmonths
(Montgomery 1983), and 12 months ( Verkes 1998). Again, there
was no evidence of a significant treatment effect between groups
(Analysis 1.1; OR 0.76, 95% CI 0.42 to 1.36; k = 3; N = 243).
The quality of evidence, assessed using the GRADE criteria, was
low (see Summary of findings for the main comparison).
To assess the efficacy of each NGA drug, the intervention arms
in Hirsch 1982 were separated into nomifensine vs. placebo (n =
76) and mianserin vs. placebo (n = 76). There was no evidence
of a significant difference between drugs (Analysis 1.2; test for
subgroup differences: Chi² = 1.25; df = 2; p = 0.53; I² = 0%).
Secondary outcomes
1.2 Treatment adherence
Data on treatment adherence was reported in one trial (Verkes
1998), however no numerical data for treatment adherence were
reported. Instead the trial authors state that “...analysis of capsule
counts at each visit revealed no statistically significant differences
between treatments” (p.545), and that “...levels of platelet sero-
tonin were not substantially decreased at week two in five patients,
indicating doubtful adherence, and showed amanifest increase fol-
lowing a previous definite decrease in four other patients-at week
8 (n = 2) and week 52 (n = 2)” (p.545).
1.3 Depression
Two trials reported outcome data for depression (Verkes 1998;
Hirsch 1982). In Verkes 1998, however, no numerical data were
reported. Instead the trial authors state there was “...no significant
treatment effect...” for this outcome (p.545). Also, although mean
scores on the HDRS were reported by Hirsch 1982, insufficient
information was provided to enable calculation of accompanying
SDs via imputation using the formula outlined by Townsend
2001.
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1.4 Hopelessness
Information on hopelessness was reported in one trial (Verkes
1998). Once again, however, no numerical data were reported.
Instead the trial authors state there was also “...no significant treat-
ment effect...” for this outcome (p.545).
1.5 Suicidal ideation
No data available.
1.6 Problem-solving
No data available.
1.7 Suicide
Numbers of suicides during follow-up were available for two trials
(Hirsch 1982; Verkes 1998). In the first, no participant died by
suicide during the six month follow-up period (Hirsch 1982).
In the second, one suicide occurred in the control group by the
12 month follow-up period; however, there was no evidence of a
significant treatment effect for NGAs on suicide in this trial (0/
46 versus 1/45; OR 0.32, 95% CI 0.01 to 8.04; k = 1; N = 91).
Comparison 2: antipsychotics versus placebo or other
comparator drug/dose
The effectiveness of ’prophylactic’ injections of the antipsychotic
flupenthixol compared to placebo was investigated in one small
trial of patients admitted to a general hospital following a “suicidal
act” (N = 37; Montgomery 1979). A second trial investigated the
effectiveness of low dose (12 mg) fluphenazine compared to ul-
tra-low dose (1.5 mg) fluphenazine in individuals admitted to an
emergency psychiatric unit following a suicide attempt (N = 58;
Battaglia 1999). The authors of this trial state that “[t]he ’ultra-low’
(1.5 mg) was chosen to represent the extreme low end of possible
pharmacologic effect for fluphenazine treatment” (p.363). How-
ever, because the comparator in these two trials was different (i.e.,
placebo in Montgomery 1979 and ultra-low dose fluphenazine in
Battaglia 1999) we have not combined the results of these two
trials in a meta-analysis.
Primary outcome
2.1 Repetition of SH
A significant treatment effect for flupenthixol was found for repe-
tition of SH in the six months following trial entry (3/14 vs. 12/
16; OR 0.09, 95% CI 0.02 to 0.50; k = 1; N = 30), although the
overall quality of evidence was very low (see Summary of findings
2).
There was no significant treatment effect for low-dose
fluphenazine, however, on repetition of SH during the six month
follow-up period (12/27 versus 9/26; OR 1.51, 95% CI 0.50 to
4.58; k = 1; N = 53). The quality of evidence for this outcome was
very low (see Summary of findings 2).
Secondary outcomes
2.2 Treatment adherence
There was no evidence of a significant treatment effect for the
number of participants who completed the full course of treatment
in Montgomery 1979 (14/18 versus 16/19; OR 0.66, 95% CI
0.12 to 3.45; k = 1; N = 37).
No data on treatment adherence were available for Battaglia 1999.
2.3 Depression
No data available.
2.4 Hopelessness
No data available.
2.5 Suicidal ideation
No data available.
2.6 Problem-solving
No data available.
2.7 Suicide
No data on suicides were available for Montgomery 1979. In
Battaglia 1999, no participant died by suicide in either group
during the six month follow-up period.
Comparison 3: mood stabilisers versus placebo
In a single trial the effectiveness of lithium was compared to
placebo in individuals who had made suicide attempts, defined
as SH acts with explicit or implicit evidence that the individual
intended to die, in the context of an depressive spectrum disorder
(N = 167; Lauterbach 2008).
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Primary outcome
3.1 Repetition of SH
There was no evidence of a significant treatment effect for lithium
on repetition of SH at the 12month follow-up period (7/84 versus
7/83; OR 0.99, 95% CI 0.33 to 2.95; k = 1; N = 167). There
was evidence of low quality for this intervention (see Summary of
findings 3). Please note that these ORs differ modestly from those
reported by the authors in correspondence; however, there is no
material difference in either the overall direction or significance of
these results.
Secondary outcomes
3.2 Treatment adherence
No data available.
3.3 Depression
There was also no evidence of a significant treatment effect for
lithium on depression at either the three month (mean 9.11, SD
7.0, n = 59 versus mean 9.45, SD 6.8, n = 51; MD -0.34, 95% CI
-2.92 to 2.24; k = 1; N = 110), six month (mean 9.48, SD 7.2, n
= 47 versus mean 8.94, SD 8.7, n = 38; MD 0.54, 95% CI -2.91
to 3.99; k = 1; N = 85), or 12 month (mean 8.48, SD 7.5, n =
31 versus mean 8.87, SD 8.1, n = 33; MD -0.39, 95% CI -4.21
to 3.43; k = 1; N = 64) follow-ups. It should be noted that these
MDs differ modestly from those reported by the authors; however,
there is no material difference in either the overall direction or
significance of these results.
3.4 Hopelessness
There was no evidence of a significant treatment effect for lithium
on hopelessness at either the three month (mean 8.91, SD 5.4, n
= 45 versus mean 9.47, SD 6.2, n = 53; MD -0.56, 95% CI -2.86
to 1.74; k = 1; N = 98), six month (mean 8.32, SD 6.4, n = 28
versus mean 9.16, SD 7.0, n = 24; MD -0.84, 95% CI -4.51 to
2.83; k = 1; N = 52), or 12 month (mean 8.88, SD 5.4, n = 26 vs.
mean 9.04, SD 6.1, n = 25; MD -0.16, 95% CI -3.33 to 3.01; k
= 1; N = 51) follow-ups. These MDs differ modestly from those
reported by the authors; however, there is no material difference
in either the overall direction or significance of these results.
3.5 Suicidal Ideation
There was no evidence of a significant treatment effect for lithium
on the number of patients reporting suicidal ideation, defined as
a score of greater than zero on the Scale for Suicidal Ideation, at
either the three month (20/58 versus 16/51; OR 1.15, 95% CI
0.52 to 2.57; k = 1; N = 109), six month (15/45 versus 11/37;
OR 1.18, 95% CI 0.46 to 3.02; k = 1; N = 82), or 12 month
(8/31 versus 11/32; OR 0.66, 95% CI 0.22 to 1.97; k = 1; N =
63) follow-ups. These ORs differ modestly from those reported
by the authors in correspondence; however, there is no material
difference in either the overall direction or significance of these
results.
3.6 Problem-solving
No data available.
3.7 Suicide
There was no evidence of a significant treatment effect for lithium
on suicides (0/84 versus 3/83; OR 0.14, CI 0.01 to 2.68; k =
1; N = 167). The authors, however, state that: “[a]ssuming the
number of rare events to be Poisson-distributed and taking the
event proportion in the placebo group as a comparison standard (3/
83=3.6%), the probability of no eventwas lower than5%...Taking
into account the available person-years that are somewhat larger
in the lithium group compared with the placebo group, it can be
shown that the 95%CI of the placebo incidence rate of completed
suicides of IR = 0.065 (range 0.013-0.190) did not cover the zero
IR of the lithium group (p = 0.049)” (p.475).
Comparison 4: natural products versus placebo
One trial investigated the effectiveness of dietary supplementation
with omega-3 essential fatty acid (n-3EFA) in patients admitted
to accident and emergency facilities following an episode of SH
(N = 49; Hallahan 2007).
Primary outcome
4.1 Repetition of SH
There was no evidence of a significant treatment effect for natural
products during the 12 week treatment phase (7/22 versus 7/27;
OR 1.33, 95%CI 0.38 to 4.62; k = 1; N = 49). This was associated
with a low quality of evidence, however (see Summary of findings
4).
Additionally, there was no difference between groups in the mean
number of SH episodes per participant between those receiving
the supplement and those receiving placebo (mean 0.41 versus
mean 0.41). However, SDs were not reported and insufficient
information was available to enable imputation of SDs using the
formula outlined by Townsend 2001 for this outcome.
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Secondary outcomes
4.2 Treatment adherence
There was no evidence of a significant treatment effect for natural
products on treatment adherence as measured by pill counts (19/
22 versus 20/27; OR 2.22, 95% CI 0.50 to 9.85; k = 1; N = 49).
4.3 Depression
Mean and SD scores on the BDI and HRSD were reported as
adjusted improvement scores. The authors report that there were
“significant improvements in BDI scores at 12 weeks (p = 0.004)
in the [omega-3] group. Moreover, more patients in the [omega-
3] group attained more than 50% (p = 0.001) and 70% (p =
0.001) reduction (response and remission respectively) in symp-
toms...Similar data were observed for the HRSD” (p.119).
4.4 Hopelessness
No data available.
4.5 Suicidal ideation
There was a significant treatment effect for natural products on
the proportion of participants reporting suicidal ideation at the
12 week follow up (8/22 versus 19/27; OR 0.24, 95% CI 0.07 to
0.80; k = 1; N = 49).
4.6 Problem-solving
No data available.
4.7 Suicide
No participant died by suicide in either group during the 12 week
treatment period.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Antipsychotics (flupenthixol, fluphenazine) compared to placebo or another comparator drug/dose for adults who engage in SH.
Patient or population: adults who engage in SH
Settings: outpatient
Intervention: antipsychotics (flupenthixol, fluphenazine)
Comparison: placebo or another comparator drug/dose
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo or another com-
parator drug/dose
Antipsychotics
Repetition of SH at six
months
(flupenthixol vs. placebo)
Study population OR 0.09
(0.02 to 0.50)
30
(1 study)
⊕©©©
very low1,2
Quality of evidence was
downgraded as this was
a single, small trial (N =
37) in which random se-
quence generation, allo-
cation concealment, and
personnel blinding were
rated as at unclear risk of
bias. Quality was further
downgraded owing to se-
rious imprecision
750 per 1000 213 per 1000
(57 to 600)
Repetition of SH at six
months
(low dose fluphenazine
vs. ultra low dose
fluphenazine)
Study population OR 1.51
(0.50 to 4.58)
53
(1 study)
⊕©©©
very low1,2
Quality of evidence was
downgraded as this was
a single, small trial (N =
53). Quality was further
downgraded owing to se-
rious imprecision
346 per 1000 444 per 1000
(209 to 708)
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*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio; SH: self-harm.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Risk of bias was rated as VERY SERIOUS as no details of allocation concealment or personnel blinding were provided leading to
possible selection, performance, and detection bias.
2 Imprecision was rated as SERIOUS as the forest plot indicates the trial was associated with a wide confidence interval.
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Mood stabilisers (lithium) compared to placebo for adults who engage in SH.
Patient or population: adults who engage in SH
Settings: outpatients
Intervention: mood stabilisers (lithium)
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Mood stabilisers
Repetition of SH at 12
months
Study population OR 0.99
(0.33 to 2.95)
167
(1 study)
⊕⊕©©
low1,2
Quality of evidence was
downgraded as this was
a single trial and there
was evidence of a signif-
icant imbalance between
the treatment and control
groups at baseline
84 per 1000 84 per 1000
(29 to 214)
*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio; SH: self-harm.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Risk of bias was rated as VERY SERIOUS as no details of allocation concealment or personnel blinding were provided leading to
possible selection, performance, and detection bias.
2 The trial was further downgraded as there was substantial imbalance between the intervention and control groups in terms of the
proportion of participants with a history of multiple suicide attempts, scores on the Suicide Intent Scale for the index attempt, and the
proportion of participants diagnosed with any personality disorder suggesting the presence of possible confounding.
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Natural products (omega-3 fatty acid supplementation) compared to placebo for adults who engage in SH.
Patient or population: adults who engage in SH
Settings: outpatients
Intervention: natural products (omega-3 fatty acid supplementation)
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Natural products
Repetition of SH dur-
ing 12 week treatment
phase
Study population OR 1.33
(0.38 to 4.62)
49
(1 study)
⊕⊕©©
low1,2
Quality of evidence
was downgraded owing
to possible performance
and detection bias and
serious imprecision
259 per 1000 318 per 1000
(117 to 618)
*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio; SH: self-harm.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Risk of bias was rated as SERIOUS as no details on outcome assessor blinding were provided leading to possible performance and
detection bias.
2 Imprecision was also rated as SERIOUS owing to the wide confidence interval associated with the estimate of treatment effect.
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D I S C U S S I O N
This systematic review is an update of previous versions of the
Cochrane review (Hawton 1998; Hawton 1999); it also adds to
rawdatawe provided to theUK’sNational Institute forHealth and
Care Excellence (NICE) in 2010 to contribute to its guideline on
longer-term management of self-harm NICE 2011). Whilst the
previous review included psychosocial interventions, this update
is solely focused on psychopharmacological treatments. Previously
we commented on the paucity of evidence on which to make firm
conclusions about themost effective formof treatment for patients
who have recently engaged in SH. In the previous versions of this
review we only focused on a limited number of clinical outcomes;
namely repetition of SH and suicide. In this update we have con-
siderably expanded the range of clinically relevant outcomes that
have been examined to include treatment adherence, depression,
hopelessness, problem-solving, and suicidal ideation where avail-
able.
In our previous reviewwe commented on the fact that themajority
of trials included either patients who had all taken overdoses, or
samples where the majority had. This appears still to be the case,
reflecting the types of patients who present to general hospitals
following SH (Hawton 2007).However, there are other important
patient subgroups, such as those who cut themselves. None of the
pharmacological trials included in this review specifically focused
on these patients. It should be noted that people who repeat SH
may change the methods they use (Lilley 2008).
None of the trials included information on adverse effects of phar-
macotherapy, other than further suicidal behaviour.
We have used the intention-to-treat method where data allowed.
This was usually possible when examining the outcomes of repe-
tition of SH and suicide. Where outcomes relied on patient inter-
view, this was generally not possible and we have instead used all
available case data.
Summary of main results
Newer generation antidepressants
Three trials in which newer generation antidepressants were eval-
uated in SH patients indicated no overall benefit or negative effect
in terms of repetition of SH compared with placebo. However, it
should be noted that the trials were relatively small and the confi-
dence intervals around the point estimate of the treatment effects
was relatively wide. As only one death by suicide was recorded it
was not possible to determine whether there is an effect of newer
generation antidepressants on suicide. In this review we combined
three newer generation antidepressants from different drug classes
(i.e., mianserin, nomifensine and paroxetine). Although we ac-
knowledge that these drugs have different mechanisms of action,
we chose to combine them for the purposes of meta-analysis on
the basis that their potential impacts on risk of SH, for example
through a serotonin-mediated reduction in impulsivity and en-
hanced emotion regulation, are likely to be similar. A post hoc
analysis, furthermore, suggested that no one antidepressant was
superior to the others in reducing repetition of SH.
Antipsychotics
In a single trial in patients with a history of multiple episodes of
SH, the use of the depot antipsychotic medication flupenthixol
appeared to have considerable benefits compared with placebo
in terms of reduced repetition of SH (Montgomery 1979). This
trial has not been replicated and similar trials have not been con-
ducted with newer oral antipsychotics, although they have been
conducted in patients with borderline personality disorder with
or without a history of SH (Stoffers 2010). In another single trial,
two different doses of fluphenazine did not appear to differ in their
impact on repetition of SH in patients with a history of multiple
episodes of SH (Battaglia 1999).
Mood Stabilisers
In a comparison of lithium versus placebo in suicide attempters
with depression, no beneficial impact of lithium was found for
repetition of SH, depression, hopelessness, or suicidal ideation
(Lauterbach 2008). It should also be noted that despite randomi-
sation the lithium-treated group differed significantly from the
placebo-treated group in terms of more patients having a history of
multiple suicide attempts and personality disorder. However, this
group had lower suicidal intent scores associated with the index
attempt.
Our analysis also did not show a beneficial effect for lithium on
suicide, although the authors claimed that there was such an effect.
This was based on there being no suicides in the lithium group and
three in the placebo group, and taking account of exposure time
in each group. While we must conclude that our result showed
no significant effect on suicide, the trend revealed evidence of a
beneficial effect of lithium on suicide and SH in affective disorders
(Cipriani 2013a), suggesting that this is an area for future research.
Natural products
In a single trial comparing provision of omega-3 essential fatty
acids with placebo (in addition to routine therapy) for patients
with a history of repeated episodes of SH, there appeared to be
no impact on further repetition of SH. However, fewer patients
who received the supplement reported suicidal ideation at follow-
up (Hallahan 2007).
Overall completeness and applicability of
evidence
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Completeness of evidence
There have been few trials of pharmacological interventions for
SH patients (we identified just seven), especially compared with
the number of trials of psychosocial treatments. Therefore our
conclusions are limited to a small range of drugs and outcomes.
Three trials focused on newer generation antidepressants. This is
in keeping with the high prevalence of depression in SH patients
in general presenting to clinical services (Hawton 2013) and with
evidence that antidepressants are commonly prescribed in SH pa-
tients (Haw 2001). However, these trials included relatively old
drugs (i.e., mianserin, nomifensine and paroxetine). The antide-
pressants now most commonly used for treatment of depression
are SSRIs, but only one older drug from this group (i.e., paroxe-
tine) has been evaluated in SH patients. Increasingly, SNRIs are
also being used for treatment of depression (Hollingworth 2010;
Ilyas 2012; Olfson 2009), but none of this group of antidepres-
sants has so far been evaluated in this clinical population. Because
of the small number of trials of antidepressants, and the lack of
clarity over the mechanism of action in relation to SH behaviour
for these agents, we have combined results for the different an-
tidepressants in order to establish whether there is evidence of a
generalised effect of antidepressants in this patient population.
Limited data were available on secondary outcomes. Only three
trials included information on depression and two on hopelessness
and suicidal ideation. Information on suicide was only published
in one trial (Lauterbach 2008) and had to be requested from au-
thors for the remaining trials.
Applicability of evidence
The gender representation of participants in these trials appears
to have been in accord with SH patients more generally (Hawton
2007). Five of the seven trials focused on individuals with a his-
tory of repeated SH, which is a particular issue in this clinical
population (Owens 2002; Zahl 2004; Carroll 2014). Only one
trial recorded information on intent of participants (Lauterbach
2008), which is surprising given the association of SH with future
risk of suicide (Owens 2002; Carroll 2014).
It should be noted that this review focused exclusively on patients
who have engaged in SH. As a result, we have excluded patients
with conditions such as borderline personality disorder who have
not engaged in SH and mixed trials of patients with either SH or
suicidal ideation in the absence of suicidal behaviour. For further
information on the treatment of patients with borderline person-
ality disorder the reader is referred to Stoffers 2010.
Quality of the evidence
The trials included in this review were likely too small to detect
significant differences in proportions of patients experiencing the
primary outcome, namely repetition of SH. Additionally, quality
of evidence, as assessed using the GRADE approach, was generally
low to very low suggesting that further research is likely to have an
important impact on our confidence in the estimate of treatment
effectiveness, and may in fact change the estimate.
Limitations in design and implementation
Five trials possessed high risk of bias in relation to at least one
aspect of trial design, with weaknesses most commonly observed
with respect to incomplete outcome data. Attrition bias therefore
cannot be ruled out. Details on personnel blinding were not re-
ported in three trials whist a further two reported no information
on outcome assessor blinding. Performance bias and detection bias
also cannot be ruled out.
Participants prescribed psychotropic medication other than the
intervention drugs were typically excluded from the majority of
the included trials (Battaglia 1999; Hallahan 2007; Hirsch 1982;
Lauterbach 2008; Verkes 1998). Information on medication use
was not reported in one trial of antipsychotics (Montgomery
1979); consequently the effect of this intervention may have been
confounded.
Indirectness of evidence
Repetition of SH was measured using either self-reported infor-
mation or hospital re-presentation in all seven trials included in
this review. Information on secondary outcomes was measured us-
ing widely validated psychometric measures (e.g., BDI, BHS) that
were not subjected to modifications in scoring.
Unexplained heterogeneity or inconsistency of results
Meta-analysis was only undertaken for newer generation antide-
pressants, for which results between trials were reasonably consis-
tent as indicated by the I2 statistic values.
Imprecision of results
Results of the individual trials included in this review were asso-
ciated with a high level of imprecision as indicated by the wide
confidence intervals around the effect size estimates.
Probability of publication bias
Presence of publication bias could not be evaluated as no meta-
analysis in the present review included 10 or more trials. However,
it is notable that one trial (Hirsch 1982) was never published in
full whilst a second (Montgomery 1979) was not published in a
peer-reviewed journal.
Potential biases in the review process
We have no reason to believe we have not identified all relevant
trials of pharmacological interventions. Nevertheless, by using the
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random-effects model in all analyses, our results possess greater
generalisability than if we had used the fixed-effect model (Erez
1996). However, because our review criteria included only trials
of patients who had all engaged in SH and presented to hospital
in the preceding six months, we excluded trials where only some
of the patients had engaged in SH and also trials where SH was an
outcome measured in general pharmacological interventions for
patients with psychiatric disorders. Data on repetition of SH were
available for all the included trials and information on suicides was
available for most (although the number of events was small).
We chose to combine three different newer generation antide-
pressants from three different drug classes in order to investigate
whether there was an overall impact of antidepressant therapy,
even though the pharmacological mechanisms of these drugs are
likely to have differed. Also, the phenothiazine drugs flupenthixol
and fluphenazine (investigated in two trials) are less often used in
clinical practice than used to be the case.
We also combined data from different time points in our analysis
of newer generation antidepressants (i.e., 12 weeks, six months,
and 12 months) to make maximal use of the limited data on the
efficacy of these drugs. This might however limit the applicability
of the results.
Agreements and disagreements with other
studies or reviews
We have identified one review of pharmacotherapy in “self-mu-
tilation”, which included a wide range of evidence, not just from
RCTs (Smith 2005). It also included trials in which not all par-
ticipants had a history of SH. While there were encouraging find-
ings, especially with regard to mood stabilisers and antipsychotics,
effects were less strong in randomised than non-randomised trials.
Another Cochrane review considered pharmacotherapy for bor-
derline personality disorder and concluded that both antipsy-
chotics and mood stabilisers could be beneficial for the core symp-
toms of the disorder but results were inconclusive for suicidal be-
haviour (Stoffers 2010).
Given the positive effects of lithium with regard to suicidal be-
haviour in patients with affective disorders found in a second
Cochrane review (Cipriani 2013a), there may also be a role for
lithium for some SH patients. Given that the review by Cipriani
2013a focused specifically on patients with either depression or
bipolar disorder, rather than those with a history of SH, it may
well be that the primary indication for lithium in the prevention
of further SH is in patients with either of these disorders. While
the negative results of the Lauterbach 2008 trial, which included
patients with “an affective spectrum disorder”, would appear con-
trary to this suggestion, it should be noted that there were no sui-
cides in the lithium-treated group.
A further Cochrane review examined pharmacological interven-
tions for self-injurious behaviour in adults with intellectual dis-
abilities (Rana 2013). The authors reported that there was weak
evidence that an opioid receptor antagonist (naltrexone) and an
antidepressant (clomipramine) were more beneficial than placebo
in reducing self-injurious behaviour in this population. However,
bias in the included trials precluded a definitive conclusion.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Given the paucity of trials, which were generally of low quality, it
is not possible to reach firm conclusions regarding pharmacologi-
cal interventions in SH patients. While depression is common in
these patients, we found no evidence that newer generation an-
tidepressants prevent repetition of SH although it should be noted
that one of these drugs, nomifensine, is no longer used in the UK.
While in a single early trial of flupenthixol in those with multi-
ple episodes of SH there was evidence of benefit for repetition of
SH, this requires replication - preferably involving more modern
antipsychotics - before such treatment can be considered for use
in routine clinical practice. While our analysis of the impact of
lithium on suicide following SH showed no effect, this differed
from the conclusion of the authors (Lauterbach 2008). Clinicians
treating SH patients with pharmacological agents must also be
aware of the extra risks of overdose in this population, and espe-
cially the relative toxicity of different drugs that might be used.
Implications for research
While the results of this review did not indicate any benefit of
newer generation antidepressants, the high prevalence of depres-
sion in SH patients (Hawton 2013), the strong association be-
tween both depression and SH and suicide, and the frequent use
of antidepressants in treatment following SH (Haw 2001) sug-
gest that there should be further evaluation of antidepressants in
this patient population. This is particularly true for patients with
a diagnosis of depression, and would preferably involve the use
of more modern and less toxic antidepressants, which could be
combined with psychosocial interventions. The apparent benefit
of flupenthixol in an old trial of its use in individuals with a his-
tory of multiple episodes of SH suggests there might be value in
conducting future trials on the use of antipsychotic drugs in sub-
groups of patients with a history of multiple episodes of SH. The
encouraging results of trials of lithium in patients with affective
disorders in terms of suicidal behaviours (Cipriani 2013a), and the
uncertainty around the impact of lithium on suicide in the one
trial included in this review, suggest that there should be further
evaluation of lithium in this patient population.
Evidence that self-injury may be associated with endorphin release
(Nock 2010), suggests that investigations of drugs that can block
opioid receptors might be of benefit to those patients that engage
in this form of SH.
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In view of the paucity of RCTs of pharmacological agents in SH
patients, perhaps reflecting difficulties in conducting these trials
due to safety considerations, valuable information about the po-
tential impacts of drug treatments on suicidal behaviour might be
gained from population-wide registry data in which information
about drug prescriptions, hospital presentations for SH, and sui-
cide are routinely recorded.
In trials of interventions in SH patients it is important that the
characteristics of the participants are described in detail, including
in addition to gender and age, details of history of SH, methods
used, degree of suicidal intent, and presence of comorbid psychi-
atric disorders. Such information could help to provide evidence
on prediction of response to medication according to clinically
relevant sub-groups.
Additionally, any pharmacological interventions in SH patients
should include a range of outcome measures, not just SH and
suicide, but also adherence, mood, and attitudes to treatment as
these may help to identify contributors to any apparent benefits or
lack of impact. It is also important that adverse effects of treatment
medication, both short- and long-term, are carefully evaluated
(including possible use of the medication for self-poisoning).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Battaglia 1999
Methods Allocation: double-blind randomisation.
Follow-up period: six months.
N lost to follow up: 5/58 (8.6%) for repetition data.
Participants Inclusion criteria: i) aged 18-65 years; ii) receiving treatment for suicide attempt that
occurred within 30 days prior to trial entry; iii) at least 2 prior suicide attempts; iv) able
to read English
Exclusion criteria: i) allergic/hypersensitive to fluphenazine; ii) tardive dyskinesia; iii)
history of neuroleptic malignant syndrome; iv) narrow angle glaucoma; v) diagnosed
with schizophrenia; vi) diagnosed with any terminal illness with less than 1 year life
expectancy; vii) pregnant or of childbearing age and not using effective birth control;
viii) current/expected to continue with treatment using medications with psychotropic
effects
Numbers: of the 58 participants, 30 were allocated to the experimental arm, and 28 to
the control arm
Profile: 44% (n = 28) were female, 100% (n = 58) had multiple episodes of SH prior to
the index attempt, 79% (n = 45) were diagnosed with substance abuse, 35% (n = 20)
with mood disorder, and 29% (n = 17) with anxiety disorder.
Source of participants: patients presenting to a psychiatric hospital, screened for history
of suicide attempts
Location: Dallas, Texas, USA.
Interventions Experimental: low dose (12 mg) fluphenazine decanoate.
Control: ultra low dose (1.5 mg) fluphenazine decanoate.
Therapist: none.
Type of therapy offered: drug therapy.
Length of treatment: six months.
Outcomes Included: i) repetition of SH according to self-report; ii) suicide.
Excluded: i) adverse effects; ii) drug and alcohol use.
Notes Source of funding: “This research was supported in part by a grant from The National
Institute of Mental Health (MH-53799) and by Mental Health Connections, a partner-
ship between Dallas County Mental Health Mental Retardation and the Department of
Psychiatry at the University of Texas South-Western Medical Centre. Funding was from
the Texas State Legislature and Dallas Country Mental Health and Mental Retardation”
(p.370)
Declaration of author interests: no details on author interests were provided.
Other: data on suicides were obtained following correspondence with authors
39Pharmacological interventions for self-harm in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Battaglia 1999 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Participants...were randomized”
(p.363)
Comment: although it is likely the random
sequence was adequately generated, with-
out further information on the method
used, this cannot be ascertained
Allocation concealment (selection bias) Unclear risk Comment:nodetails on allocation sequence
were provided.
Blinding (performance bias and detection
bias)
Of participants
Low risk Quote: treatment described as “double-
blinded” (p.364)
Comment: given this was a drug trial, treat-
ment could have been adequately blinded
through, for example, the use of identi-
cal capsules for both the active agent and
placebo
Blinding (performance bias and detection
bias)
Of personnel
Low risk Quote: “The research nurse and research
psychiatrist...[were] both blinded to dose
group” (p.364)
Blinding (performance bias and detection
bias)
Of outcome assessors
Low risk Quote: “The research nurse and research
psychiatrist...[were] both blinded to dose
group” (p.364). However, the authors also
note that “measurement of side-effects may
have potentially unblinded the clinician
raters to dose group...“ (p.364), neverthe-
less, the authors suggest that ”...these low
rates [of side-effects] suggest the impactwas
minimal” (p.364)
Comment: given the low rate of adverse
side-effects observed, it is unlikely themea-
surement of side-effects would have led to
complete unblinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: of the 58 participants, 53 com-
pleted one month and 23 completed all
six months of treatment. Intention-to-treat
analyses were not provided, however
Selective reporting (reporting bias) Unclear risk Comment: data on suicides were obtained
from authors, suggesting that selective re-
porting bias may have been present. In the
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Battaglia 1999 (Continued)
absence of the trial protocol, however, the
degree of selective reporting cannot be as-
certained
Other bias Low risk Comment: no apparent other sources of
bias.
Hallahan 2007
Methods Allocation: computer generated list. Randomisation code was revealed to researchers only
after data collection was complete
Follow-up period: 12 weeks.
N lost to follow up: 0/49 (0%) for repetition of SH.
Participants Inclusion criteria: i) presenting to hospital following an episode of SH; ii) at least one
previous episode of SH; iii) living inside the greater Dublin area
Exclusion criteria: i) current history of addiction, substance abuse, psychosis, or an eating
disorder; ii) currently receiving psychotherapy; iii) history of dyslipidaemia; iv) involved
with any treatment, diet, or illness known to interfere with lipid or n-3 EFAmetabolism;
v) weight loss greater than 10% over the previous 3 months; vi) taking supplements
containing n-3 EFAs or have consumed fish more than once per week; vii) changes to,
or introduction of, psychotropic medication during the previous 6 weeks
Numbers: of the 49 participants, 22 were allocated to the experimental arm, and 27 to
the control arm
Profile: 65% (n = 32) were female, 100% (n = 49) had multiple episodes of SH prior
to the index episode, 41% (n = 20) were diagnosed with alcohol misuse, 81.6% (n =
40) were diagnosed with any personality disorder, and 71.4% (n = 35) were diagnosed
with borderline personality disorder. Additionally, 53% (n = 26) were currently taking
psychotropic medication.
Source of participants: patients presenting to hospital following an episode of SH.
Location: Dublin, Republic of Ireland.
Interventions Experimental:EPAX 5500 in addition to usual psychiatric care. Participants received four
capsules containing 305 mg EPA and 227 mg DHA daily. Total dose equalled 2128 mg
per day of EPA plus DHA
Control: placebo in addition to usual psychiatric care. Participants received four capsules
per day consisting of 99% corn oil and a 1% EPA/DHA mixture
Therapists: not applicable.
Type of therapy offered: dietary supplement.
Length of treatment: 12 weeks.
Outcomes Included: i) repetition of SH according to hospital records; ii) treatment adherence; iii)
depression; iv) suicidal ideation; v) suicide
Excluded: i) aggression; ii) adverse effects; iii) impulsivity; iv) stress
Notes Source of funding: “B.H. received salary support from the Department of Psychiatry,
University of Illonois at Chicago, USA” (p.122)
Declaration of author interests: “Pronova (now Epax) AS, Lysaker, Norway, provided the
active preparation and placebo but were not otherwise involved in the study” (p.118).
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Hallahan 2007 (Continued)
No other conflicts of interest were stated
Other: adherence was encouraged by weekly telephone calls and was determined by pill
counts
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “An independent colleague dis-
pensed either active or placebo capsules ac-
cording to a computer-generated list” (p.
119)
Comment: use of a computer-generated list
is likely to have minimised the role of bias
in the generation of the randomisation se-
quence
Allocation concealment (selection bias) Low risk Comment: no details about allocation con-
cealment were provided, however, the col-
league responsible for allocation was re-
ferred to as “independent” suggesting that
allocation may have been adequately con-
cealed
Blinding (performance bias and detection
bias)
Of participants
Low risk Quote: “Participants were prescribed four
identical capsules of either active agent or
placebo” (p.119)
Comment: use of identical capsules for both
the active agent and placebo arms means
that participant blinding could have been
achieved
Blinding (performance bias and detection
bias)
Of personnel
Low risk Quote: “An independent colleague dis-
pensed either active or placebo capsules ac-
cording to a computer-generated list. This
code was only revealed to the researchers
once data collection was complete” (p.119)
Comment: use of identical capsules for both
the active agent and placebo arms means
that personnel blinding could have been
achieved
Blinding (performance bias and detection
bias)
Of outcome assessors
Unclear risk Comment: no details on outcome assessor
blinding were provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “Analyses were performed using.
..the last observation carried forward...
method” (p. 119)
Comment: thirteen participants dropped
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Hallahan 2007 (Continued)
out of the trial. Reasons given, for those al-
located to the treatment arm, included: i)
leaving the district (n = 2); ii) lost to fol-
low-up (n = 2); iii) admitted to a psychi-
atric hospital at time 1 (n = 2); iv) ’late’ dis-
continuation (n = 1). Reasons for drop-out
for those randomised to the control arm in-
cluded: i) ’late’ discontinuation (n = 3); ii)
lost to follow-up (n = 2); iii) left district (n
= 1).
Selective reporting (reporting bias) Unclear risk Comment: no reason to suspect that all out-
comes were not measured, however, in the
absence of the trial protocol, this cannot be
ascertained
Other bias Low risk Comment: no apparent other sources of
bias.
Hirsch 1982
Methods Allocation: randomised placebo-controlled trial.
Follow-up period: 12 weeks.
N lost to follow-up: 0/114 (0%) for repetition of SH data.
Participants Inclusion criteria: i) General Health Questionnaire score of over 20.
Exclusion criteria: i) currently receiving antidepressant or antipsychotic medication
Numbers: of the 114 participants, 76 were allocated to the experimental arm and 38 to
the control arm
Profile: not stated.
Source of participants: patients admitted to hospital following an episode of deliberate
self-poisoning
Location: London, UK.
Interventions Experimental: oral administration of either 30-60 mg/day of mianserin or 75-150 mg/
day of nomifensine
Control: placebo.
Therapist: none.
Type of therapy offered: drug therapy.
Length of treatment: six weeks.
Outcomes Included: i) repetition of SH according to an unknown source; ii) suicide
Excluded: i) depression; ii) GHQ scores; iii) life events; iv) treatment adherence
Notes Source of funding: no details on funding were provided.
Declaration of author interests: no details on author interests were provided.
Other: data on depression and treatment adherence were excluded due to inability to
collect unpublished data relating to these outcomes
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “...randomised...” (p.307).
Comment: although it is likely the random
sequence was adequately generated, with-
out further information on the method
used, this cannot be ascertained
Allocation concealment (selection bias) Unclear risk Comment: no details on allocation conceal-
ment were provided.
Blinding (performance bias and detection
bias)
Of participants
Low risk Comment: the nature of this trialmeans that
participants are likely to have been blinded
to allocation, possibly through the use of
identical capsules for both the active agent
and placebo arms
Blinding (performance bias and detection
bias)
Of personnel
Unclear risk Comment: no details on personnel blinding
were provided.
Blinding (performance bias and detection
bias)
Of outcome assessors
Unclear risk Comment: no details on outcome assessor
blinding were provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: no details on incomplete out-
come data analyses were provided
Selective reporting (reporting bias) High risk Comment: study authors claim that various
outcomes are not significant, e.g., changes
in GHQ and depression scores post-treat-
ment, however, no numerical data are re-
ported to support these conclusions, sug-
gesting that selective reporting bias may
have been present
Other bias Low risk Comment: no apparent other sources of
bias.
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Lauterbach 2008
Methods Allocation: random assignment using a computerised randomisation sequence
Follow-up period: 14 months.
N lost to follow up: 22/169 (13.0%) at 1 month; 50/169 (29.6%) at 3 months; 62/169
(36.7%) at 6 months; 97/169 (57.4%) at 12 months
Participants Inclusion criteria: i) at least 18 years of age; ii) suicide attempt within 3 months prior to
first drug administration; iii) suicide attempt occurred within the context of a depressive
spectrum disorder; iv) able to complete the screening and baseline assessment protocols;
v) able to provide written informed consent
Exclusion criteria: i) diagnosed with a disorder associated with frequent suicidal behaviour
(e.g., schizophrenia, borderline personality disorder, severe SH and/or substance-related
disorders including current substance addictions); ii) diagnosed with any disorder indi-
cated for long-term lithium treatment; iii) diagnosed with any disorder for which lithium
treatment is contraindicated; iv) any other contraindications (e.g., pregnant, breast-feed-
ing, etc.)
Numbers: of the 167 participants, 84 were allocated to the experimental arm and 83 to
the control arm
Profile: 96 (57.5%) were female, 74 (44.3%) had multiple episodes of SH prior to the
index attempt, 123 (76%) were diagnosed with major depression
Source of participants: patients admitted to one of five participating emergency depart-
ments following a suicide attempt
Location: various locations around Germany.
Interventions Experimental: oral administration of lithium carbonate according to a fixed schedule
of dose augmentation (i.e., 200 mg/week) until an effective blood level of between 0.
6-0.8 mmol/L had been achieved. For most participants, this level was achieved in 3-
4 weeks. Pariticipants received, in addition, treatment as usual involving consultations
with physicians in the community and referral to psychiatric treatment as necessary
Control: oral administration of a placebo capsule in addition to treatment as usual involv-
ing consultations with physicians in the community and referral to psychiatric treatment
as necessary. Ingredients for the placebo capsule are not provided
Therapist: none.
Type of therapy offered: drug therapy.
Length of treatment: 12 months.
Outcomes Included: i) repetition of SH according to self-report; ii) depression (through correspon-
dence); iii) hopelessness (through correspondence); iv) suicidal ideation (through corre-
spondence); v) suicide according to an unknown source
Excluded: none.
Notes Source of funding: “This research was supported by grants 01GI 9920 and 01GI 0220
from theGermanMinistry for Education and Researchwithin the promotional emphasis
’German Research Network on Depression ’ (subproject 1.2), and German Research
Foundation grant LA 1975/2-1 to Erik Lauterback. Additional funding was granted by
Sanofi-Aventis” (p.477)
Declaration of author interests: “Dr. Ahrens has received a research grant from Sanofi-
Aventis” (p.477)
Risk of bias
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Lauterbach 2008 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Participants were randomly as-
signed...using a computerised randomisa-
tion sequence” (p.471)
Comment: use of a computerised randomi-
sation sequence is likely to have minimised
the role of bias in the generation of the ran-
domisation sequence
Allocation concealment (selection bias) Unclear risk Comment: no details on allocation conceal-
ment were provided.
Blinding (performance bias and detection
bias)
Of participants
Low risk Quote: “Double-blind assessment was con-
ducted...although in some cases this proce-
dure could not be maintained because of
emergencies in relation to suicidal acts or
insufficient drug compliance” (p.471)
Comment: the nature of this trialmeans that
participants are likely to have been blinded
to allocation, possibly through the use of
identical capsules for both the active agent
and placebo arms
Blinding (performance bias and detection
bias)
Of personnel
Unclear risk Quote: “...monitoring of lithium blood lev-
els occurred in an independent laboratory...
to ensure the double-blind design, fake val-
ues on a randomised basis were provided
for blood samples from individuals belong-
ing to the placebo group” (p.472)
Comment: as no specific details on blinding
of personnel were provided, it is unclear if
all personnel were blinded to allocation
Blinding (performance bias and detection
bias)
Of outcome assessors
Low risk Quote: “Double-blind assessment was con-
ducted...although in some cases this proce-
dure could not be maintained because of
emergencies in relation to suicidal acts or
insufficient drug compliance” (p.471)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “The evaluation of efficacy was
based on an intention-to-treat analysis, in-
cluding all participants randomised in the
trial” (p.472)
Selective reporting (reporting bias) Unclear risk Comment: no reason to suspect that all out-
comes were not measured, although in the
absence of the trial protocol, this cannot be
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Lauterbach 2008 (Continued)
ascertained
Other bias High risk Comment: significant imbalances between
the intervention and control groups were
apparent for the following characteristics:
i) proportion with a history of multiple
suicide attempts; ii) proportion diagnosed
with any personality disorder; iii) scores on
the Suicide Intent Scale for the index at-
tempt
Montgomery 1979
Methods Allocation: random allocation.
Follow-up period: six months.
N lost to follow up: 7/37 (19%) for repetition of SH.
Participants Inclusion criteria: i) documented history of two or more episodes of SH.
Exclusion criteria: i) diagnosis of depression or schizophrenia; ii) diagnosis of an organic
illness
Numbers: of the 37 participants, 18 were allocated to the experimental arm and 19 to
the control arm
Profile: 70.3% (n = 26) were female, 100% (n = 37) had multiple episodes of SH prior
to the index episode.
Source of participants: patients admitted to a general hospital following a suicidal act
Setting:Maidstone, UK.
Interventions Experimental: intramuscular administration of 20 mg flupenthixol decanoate
Control: placebo.
Therapist: none.
Type of therapy offered: drug therapy.
Length of treatment: six months.
Outcomes Included: i) repetition of SH according to an unknown source; ii) treatment adherence
Excluded: i) adverse effects.
Notes Source of funding: no details on funding were provided.
Declaration of author interests: no details on author interests were provided.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly allocated”
(p.227).
Comment: although it is likely the random
sequence was adequately generated, with-
out further information on the method
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Montgomery 1979 (Continued)
used, this cannot be ascertained
Allocation concealment (selection bias) Unclear risk Comment: no details on allocation conceal-
ment were provided.
Blinding (performance bias and detection
bias)
Of participants
Low risk Quote: “Patients...remained blind to actual
treatment” (p.227).
Comment: the nature of this trialmeans that
participants are likely to have been blinded
to allocation, possibly through the use of
identical capsules for both the active agent
and placebo arms
Blinding (performance bias and detection
bias)
Of personnel
Unclear risk Comment: no details on personnel blinding
were provided.
Blinding (performance bias and detection
bias)
Of outcome assessors
Low risk Quote: “...and raters remained blind to ac-
tual treatment” (p.227)
Comment: assuming ‘raters’ are outcome
assessors, then outcome assessors were
blinded as to allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were seven dropouts. Rea-
sons for drop-out included: i) development
of Parkinsonian side-effects necessitating
the removal of these patients to preserve
blinding (n = 2); ii) unspecified reasons (n
= 5; 2 in the experimental arm and 3 in the
control arm). No attempt was made to use
intention-to-treat analyses
Selective reporting (reporting bias) Unclear risk Comment: no reason to suspect that all out-
comes were not measured, however, in the
absence of the trial protocol, this cannot be
ascertained
Other bias Low risk Comment: no apparent other sources of
bias.
Montgomery 1983
Methods Allocation: random allocation.
Follow-up period: six months.
N lost to follow up: 0/58 (0%) for repetition of SH.
Participants Inclusion criteria: i) multiple previous episodes of SH; ii) diagnosis of personality disorder
Exclusion criteria: ii) diagnosis of depression or schizophrenia.
Numbers: of the 58 participants, 17 were allocated to the experimental arm and 21 to
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Montgomery 1983 (Continued)
the control arm
Profile: 38 (66%) were female, 58 (100%) had multiple episodes of SH prior to the
index episode, and 58 (100%) were diagnosed with personality disorder (borderline or
histrionic)
Source of participants: patients admitted to a medical ward following SH.
Location: London, UK.
Interventions Experimental: mianserin 30 mg daily.
Control: placebo.
Therapist: none.
Type of therapy offered: drug therapy.
Length of treatment: six months.
Outcomes Included: i) repetition of SH according to an unknown source.
Excluded: i) depression; ii) compliance.
Notes Source of funding: no details on funding were provided.
Declaration of author interests: no details on author interests were provided.
Other:means and SDs were missing for theMontomery-Åsberg Depression Rating Scale
necessitating the omission of this outcome
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “[Participants were r]andomly allo-
cated...” (p.184S).
Comment: although it is likely the random
sequence was adequately generated, with-
out further information on the method
used, this cannot be ascertained
Allocation concealment (selection bias) Unclear risk Comment: no details on allocation conceal-
ment were provided.
Blinding (performance bias and detection
bias)
Of participants
Low risk Quote: “Randomly allocated to treat-
ment under double-blind conditions...” (p.
184S)
Comment: the nature of this trialmeans that
participants are likely to have been blinded
to allocation, possibly through the use of
identical capsules for both the active agent
and placebo arms
Blinding (performance bias and detection
bias)
Of personnel
Low risk Quote: “Randomly allocated to treat-
ment under double-blind conditions...” (p.
184S)
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Montgomery 1983 (Continued)
Blinding (performance bias and detection
bias)
Of outcome assessors
Low risk Quote: “Randomly allocated to treat-
ment under double-blind conditions...” (p.
184S)
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Drop out rate of 34%” (p.185S).
Comments: subsequent analyses include
only those in the experimental and control
groups who completed treatment, suggest-
ing per protocol analyses were undertaken.
Selective reporting (reporting bias) Unclear risk Comment: no reason to suspect that all out-
comes were not measured, however, in the
absence of the trial protocol, this cannot be
ascertained
Other bias Low risk Comment: no apparent other sources of
bias.
Verkes 1998
Methods Allocation: randomised assignment.
Follow-up period: 12 months.
N lost to follow up: 0/91 (0%) for repetition of SH data.
Participants Inclusion criteria: i) aged 18 years and over; ii) previous history of SH.
Exclusion criteria: i) current diagnosis of major depression.
Numbers: of the 91 participants, 46 were allocated to the experimental arm and 45 were
allocated to the control arm
Profile: 100% (n = 91) had multiple episodes of SH prior to the index episode, 92%
(n = 84) were diagnosed with a personality disorder, 6.5% (n = 6) were diagnosed with
dysthymia, 4.4% (n = 4) were diagnosed with an anxiety disorder, 8.8% (n = 8) were
diagnosed with dissociative disorder, 44% (n = 40) were diagnosed with alcohol abuse,
20.9% (n = 19) were diagnosed with adjustment disorder, 25.3% (n = 23) were diagnosed
with depressive disorder, and 16.5% (n = 15) had no psychiatric diagnosis.
Source of participants: patients were recruited from outpatient departments in accident
and emergency wards of university hospitals in Leiden and Rotterdam
Location: Leiden and Rotterdam, the Netherlands.
Interventions Experimental: paroxetine 40 mg/day, plus weekly or fortnightly psychotherapy
Control: placebo, plus weekly or fortnightly psychotherapy.
Therapist: none.
Type of therapy offered: drug therapy.
Length of treatment: 12 months.
Outcomes Included: i) repetition of SH according to an unknown source; ii) treatment adherence;
iii) depression; iv) hopelessness; v) suicide
Excluded: i) adverse effects; ii) anger; iii) side-effects.
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Verkes 1998 (Continued)
Notes Source of funding: “Supported by grant 89-110 CRO 012859 from the Dutch Ministry
of Welfare, Health, and Cultural Affairs and a grant from SmithKline Beecham Phar-
maceuticals” (p.543)
Declaration of author interests: no details on author interests are provided.
Other: authors note that “the number of previous suicide attempts...was manifestly as-
sociated with the risk of another suicide attempt.... With adjustment for this important
predictive characteristic, paroxetine proved to reduce the recurrence of suicidal behavior
significantly” (p.544-555)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomly assigned”
(p.544)
Comments: correspondence with authors
clarified that “all the medication...was
packed in a series of blisters with consec-
utive numbers. This was done before the
start of the study...A patient who entered
the study got a consecutive number and
subsequently received the medication blis-
ters with the corresponding number.”
Allocation concealment (selection bias) Low risk Comments: correspondence with authors
clarified that randomisationwas done at the
pharmacy of SmithKline Beecham. Use of
offsite allocation means that allocation was
probably adequately concealed
Blinding (performance bias and detection
bias)
Of participants
Low risk Quote: “Patients in the placebo group re-
ceived matching placebo” (p.544)
Comment: the nature of this trialmeans that
participants are likely to have been blinded
to allocation, possibly through the use of
identical capsules for both the active agent
and placebo arms
Blinding (performance bias and detection
bias)
Of personnel
Low risk Comment: use of identical capsules for both
the active agent and placebo arms means
that personnel blinding could have been
achieved
Blinding (performance bias and detection
bias)
Of outcome assessors
Unclear risk Comment: no details on outcome assessor
blinding were provided.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Efficacy was analyzed on an in-
tention-to-treat basis; all available obser-
vations were used without the last point
carried forward or estimating missing val-
ues.We also analyzed efficacy excluding the
non-compliant visits” (p.544)
Selective reporting (reporting bias) High risk Comment: numerical data were not pro-
vided for outcomes that were not signifi-
cant, for example: i) treatment adherence;
ii) depression; iii) hopelessness, suggesting
that selective reporting bias may have been
present
Other bias Low risk Comment: no apparent other sources of
bias.
SH: self-harm
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ciprani 2013 Participants were not required to have engaged in SH prior to trial entry
Gibbons 2012 Participants were not required to have engaged in SH prior to trial entry
Kelip 2010 Participants were not required to have engaged in SH prior to trial entry
Meltzer 2003 Participants were not required to have engaged in SH prior to trial entry
Nickel 2006 Participants were not required to have engaged in SH prior to trial entry
Oquendo 2011 Participants could have engaged in SH at any point, rather than within six months
Pompili 2012 Participants were not required to have engaged in SH prior to trial entry
Price 2014 Participants were not required to have engaged in SH prior to trial entry
Reeves 2008 Participants were not required to have engaged in SH prior to trial entry
Roth 2012 Participants were not required to have engaged in SH prior to trial entry
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Rucci 2011 Participants were not required to have engaged in SH prior to trial entry
Sandman 2008 Control participants were not required to have engaged in SH prior to trial entry
Characteristics of ongoing studies [ordered by study ID]
Liang 2014
Trial name or title Lithium for suicidal behavior in mood disorders (Li+)
Trial Registration Number: NCT01928446.
Methods Allocation: double-blind randomisation.
Design: multi-centre.
Setting: Department of Veterans Affairs hospitals.
Location: various locations throughout the USA.
Follow-up period: 12 months.
Participants Inclusion criteria: i)males and females; ii) any age; iii) attempted suicide within threemonths of randomisation,
or were admitted to a mental health inpatient unit within three months of randomisation specifically for the
prevention of suicide; iv) diagnosed, according to DSM-IV-TR criteria, with bipolar I disorder, bipolar II
disorder, or current or recurrent major depression
Exclusion criteria: i) diagnosis of schizophrenia or schizoaffective disorder; ii) scoring below 10 on the Brief
OrientationMemory andConcentration Test indicating presence of amajor cognitive impairment; iii) lacking
decision-making capacity according to scores on Jeste’s Brief Instrument for Assessing Decisional Capacity; iv)
adjudicated as incompetent and have been appointed a guardian or conservator; v) six or more prior lifetime
suicide attempts; vi) current or recent (within six months) use of lithium; vii) a history of adverse reactions
to lithium; viii) diagnosed with congestive heart failure according to Framingham criteria; ix) diagnosed with
chronic renal failure as defined by the Kidney Foundation Outcome Quality Initiative criteria; x) pregnant,
may become pregnant, or using an unreliable method of birth control; xi) lactating or breastfeeding; xii)
concurrently prescribed any diuretic medications, angiotensin converting enzyme inhibitors, angiotensin II
receptor antagonists, haloperidol or clozapine; xiii) currently abusing alcohol, cocaine, methamphetamines,
other stimulants, hallucinogens, or cannabis; xiv) enrolled in another randomised controlled trial
Interventions Individuals randomised to the intervention arm will receive oral administration of extended release lithium
carbonate. Participants will be started on 600 mg/day until a steady blood plasma concentration of between
0.6 to 0.8 meg/litre is reached. Lithium will be prescribed for the duration of the 12 month follow-up period
Outcomes Primary outcome measure: time until first repeated episode of either a suicide attempt or re-hospitalisation for
the prevention of suicide
Starting date Start date: August, 2014.
Proposed end date: August, 2018.
Contact information Name: Dr. Matthew Liang and Ms. Natalie Morgenstern.
Affiliations: Department of Veterans Affairs, Boston, USA.
emails: Matthew.Liang@va.gov or Natalie.Morgenstern@va.gov
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Notes Ms. Natalie Morgenstern very kindly confirmed the information provided in this record is correct
Sharon 2014
Trial name or title Oral ketamine for suicidal ideation.
Trial registration number:NCT02037503.
Methods Allocation: double-blind randomisation.
Design: single-centre (hospital).
Setting: ambulatory patients living in the community.
Follow-up period: participants will be assessed each week during treatment for a total of three weeks, followed
by a one week post-treatment follow-up period
Location: Tel Aviv, Israel.
Participants Inclusion criteria: i) males and females; ii) between 18 and 65 years of age; iii) admitted to the emergency
department following a suicide attempt severe enough to necessitate medical intervention
Exclusion criteria: not stated.
Interventions Participants randomised to the intervention arm will receive oral administration of a sub-anaesthetic dose of
ketamine
Outcomes Primary outcome: scores on the Beck Scale for Suicidal ideation during treatment and for one week post-
treatment
Secondary outcomes: scores on Montgomery-Åsberg Depression Rating Scale during treatment and for one
week post-treatment, treatment adherence measured as the proportion of patients who withdraw from the
trial owing to the development of intolerable side-effects, and the proportion of patients who engage in SH
and/or make a suicide attempt during treatment and for one week post-treatment
Starting date Start date: January, 2014.
Proposed end date: January, 2016.
Contact information Name: Dr. Haggai Sharon.
Affiliation: Functional Brain Centre, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel
email: haggais@tlvmc.gov.il
Notes Prof. Haggai Sharon very kindly provided unpublished information relating to this trial
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D A T A A N D A N A L Y S E S
Comparison 1. Newer generation antidepressants versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Repetition of SH at last
follow-up
3 243 Odds Ratio (M-H, Random, 95% CI) 0.76 [0.42, 1.36]
2 Repetition of SH at last
follow-up (by NGA drug)
3 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Mianserin vs. Placebo 2 114 Odds Ratio (M-H, Random, 95% CI) 1.18 [0.42, 3.29]
2.2 Nomifensine vs. Placebo 1 76 Odds Ratio (M-H, Random, 95% CI) 0.81 [0.22, 2.91]
2.3 Paroxetine vs. Placebo 1 91 Odds Ratio (M-H, Random, 95% CI) 0.55 [0.24, 1.29]
Analysis 1.1. Comparison 1 Newer generation antidepressants versus placebo, Outcome 1 Repetition of SH
at last follow-up.
Review: Pharmacological interventions for self-harm in adults
Comparison: 1 Newer generation antidepressants versus placebo
Outcome: 1 Repetition of SH at last follow-up
Study or subgroup NGAs Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hirsch 1982 15/76 6/38 31.8 % 1.31 [ 0.46, 3.71 ]
Montgomery 1983 8/17 12/21 20.7 % 0.67 [ 0.18, 2.41 ]
Verkes 1998 15/46 21/45 47.5 % 0.55 [ 0.24, 1.29 ]
Total (95% CI) 139 104 100.0 % 0.76 [ 0.42, 1.36 ]
Total events: 38 (NGAs), 39 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.64, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours NGAs Favours placebo
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Analysis 1.2. Comparison 1 Newer generation antidepressants versus placebo, Outcome 2 Repetition of SH
at last follow-up (by NGA drug).
Review: Pharmacological interventions for self-harm in adults
Comparison: 1 Newer generation antidepressants versus placebo
Outcome: 2 Repetition of SH at last follow-up (by NGA drug)
Study or subgroup NGAs Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mianserin vs. Placebo
Hirsch 1982 10/38 6/38 54.4 % 1.90 [ 0.61, 5.91 ]
Montgomery 1983 8/17 12/21 45.6 % 0.67 [ 0.18, 2.41 ]
Subtotal (95% CI) 55 59 100.0 % 1.18 [ 0.42, 3.29 ]
Total events: 18 (NGAs), 18 (Placebo)
Heterogeneity: Tau2 = 0.17; Chi2 = 1.44, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.32 (P = 0.75)
2 Nomifensine vs. Placebo
Hirsch 1982 5/38 6/38 100.0 % 0.81 [ 0.22, 2.91 ]
Subtotal (95% CI) 38 38 100.0 % 0.81 [ 0.22, 2.91 ]
Total events: 5 (NGAs), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
3 Paroxetine vs. Placebo
Verkes 1998 15/46 21/45 100.0 % 0.55 [ 0.24, 1.29 ]
Subtotal (95% CI) 46 45 100.0 % 0.55 [ 0.24, 1.29 ]
Total events: 15 (NGAs), 21 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Chi2 = 1.25, df = 2 (P = 0.53), I2 =0.0%
0.2 0.5 1 2 5
Favours NGAs Favours placebo
A D D I T I O N A L T A B L E S
Table 1. Major categories of psychiatric diagnoses in included studies
Refer-
ence
Psychiatric Diagnosis1
MDD
n (%)
Any
Mood
Disorder
AD
n (%)
PTSD
n (%)
AUD
n (%)
DUD
n (%)
SUD
n (%)
Adjust-
ment
BPD
n (%)
PD
n (%)
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Table 1. Major categories of psychiatric diagnoses in included studies (Continued)
n (%) Disorder
n (%)
Battaglia
1999
33 (57.9) 11 (19.0) 33 (58.0) 16 (28.0) 8 (14.0) 49 (85.0) 2
Hallahan
2007
35 (71.4) 40 (81.6)
Hirsch
19823
Lauter-
bach
2008
127 (76.
0)
8 (4.8) 12 (7.2) 14 (8.4) 32 (19.2) 131 (42.
7)
Mont-
gomery
19793
Mont-
gomery
1983
30 (78.9) 12 (31.6)
Verkes
1998
29 (31.9) 4 (4.4) 40 (43.9) 19 (20.9)
MDD:major depression disorder; AD: anxiety disorder; PTSD: post-traumatic stress disorder; AUD: alcohol use disorder;DUD: drug
use disorder; SUD: substance use disorder; BPD: borderline personality disorder; PD: any other personality disorder (not including
borderline personality disorder).
1 All diagnoses represent current rather than lifetime diagnoses. Percentages for any one trial may be greater than 100% due to
comorbidity.
2 As participants could be diagnosed with more than one psychiatric diagnosis, the absolute number of participants diagnosed with
any other personality disorder in this trial is unclear.
3 No information on psychiatric diagnoses reported.
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A P P E N D I C E S
Appendix 1. CCDANCTR search strategy
Date range searched: 01.01.56 to 02.09.14.
#1. ((deliberat* or self*) NEXT (destruct* or harm* or injur* or mutilat* or poison*)):ab,ti,kw,ky,emt,mh,mc
#2. DSH:ab
#3. (parasuicid* or “para suicid*”)
#4. (suicid* NEAR2 (attempt* or episod* or frequen* or future or histor* or multiple or previous* or recur* or repeat* or repetition)):
ab,ti,kw,ky,emt,mh,mc
#5. “post suicid*”
#6. (suicid* and (BPD or “borderline personality disorder”))
#7. (overdos* or “over dos*”)
#8. ((crisis or suicid*) NEAR (emergenc* or hospital or outpatient or “repeat* attend*” or “frequent* attend*” )):ab,ti,kw,ky,emt,mh,mc
#9. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8)
[ab:abstract; ti:title; kw:keywords; ky:additional keywords; emt:EMTREE headings; mh:MeSH headings; mc:MeSH checkwords]
Appendix 2. EMBASE, MEDLINE, PreMEDLINE, PsycINFO and CENTRAL Search Strategies
Search Strategy 2012 to 2013:
EMBASE, MEDLINE, PreMEDLINE, PsycINFO (OVID SP interface)
Date range searched: 01.01.1998 to 13.10.2013.
1. automutilation/ or drug overdose/ or exp suicidal behavior/
2. 1 use emez
3. overdose/ or self-injurious behavior/ or self mutilation/ or suicide/ or suicidal ideation/ or suicide, attempted/
4. 3 use mesz, prem
5. drug overdoses/ or self destructive behavior/ or exp self injurious behavior/ or attempted suicide/ or suicidal ideation/ or suicide/ or
suicide prevention/ or suicide prevention centers/ or suicidology/
6. 5 use psyh
7. (auto mutilat$ or automutilat$ or cutt$ or head bang$ or head bang$ or overdos$ or (self adj2 cut$) or self destruct$ or selfdestruct$
or self harm$ or selfharm$ or self immolat$ or selfimmolat$ or self inflict$ or selfinflict$ or self injur$ or selfinjur$ or selfmutilat$ or
self mutilat$ or self poison$ or selfpoison$ or suicid$).ti,ab.
8. or/2,4,6-7
9. exp “clinical trial (topic)”/ or exp clinical trial/ or crossover procedure/ or double blind procedure/ or placebo/ or randomization/ or
random sample/ or single blind procedure/
10. 9 use emez
11. exp clinical trial/ or exp “clinical trials as topic”/ or cross-over studies/ or double-blind method/ or placebos/ or random allocation/
or single-blind method/
12. 11 use mesz, prem
13. (clinical trials or placebo or random sampling).sh,id.
14. 13 use psyh
15. (clinical adj2 trial$).ti,ab.
16. (crossover or cross over).ti,ab.
17. (((single$ or doubl$ or trebl$ or tripl$) adj2 blind$) or mask$ or dummy or doubleblind$ or singleblind$ or trebleblind$ or
tripleblind$).ti,ab.
18. (placebo$ or random$).ti,ab.
19. treatment outcome$.md. use psyh
20. animals/ not human$.mp. use emez
21. animal$/ not human$/ use mesz
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22. (animal not human).po. use psyh
23. (or/10,12,14-19) not (or/20-22)
24. 8 and 23
CENTRAL (Wiley interface)
Date range searched: 01.01.1998 to 13.10.2013.
#1. MeSH descriptor: [Drug Overdose], this term only
#2. MeSH descriptor: [Self-Injurious Behavior], this term only
#3. MeSH descriptor: [Self Mutilation], this term only
#4. MeSH descriptor: [Suicide], this term only
#5. MeSH descriptor: [Suicide, Attempted], this term only
#6. MeSH descriptor: [Suicidal Ideation], this term only
#7. auto mutilat*“ or automutilat* or cutt* or ”head bang*“ or headbang* or overdos* or ”self destruct*“ or selfdestruct* or ”self
harm*“ or selfharm* or ”self immolat*“ or selfimmolat* or ”self inflict*“ or selfinflict* or ”self injur*“ or selfinjur* or selfmutilat* or
”self mutilat*“ or ”self poison*“ or selfpoison* or suicid*:ti
#8. ”auto mutilat*“ or automutilat* or cutt* or ”head bang*“ or ”head bang*“ or overdos* or ”self destruct*“ or selfdestruct* or ”self
harm*“ or selfharm* or ”self immolat*“ or selfimmolat* or ”self inflict*“ or selfinflict* or ”self injur*“ or selfinjur* or selfmutilat* or
”self mutilat*“ or ”self poison*“ or selfpoison* or suicid*:ab
#9. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
Appendix 3. Journals hand-searched for relevant literature in the original version of this review
1. Archives of Suicide Research (1995-1998).
2.Crisis (1980-1998).
3. Suicide and Life-Threatening Behavior (1971-1998).
4. Der Nervenarzt (1950-1979).
5. Journal of Adolescence (1978-1996).
6. Journal of Affective Disorders (1994-1996).
7. Journal of the American Academy of Child and Adolescent Psychiatry (1978-1996).
8. Journal of Clinical Psychiatry (1978-1996).
9. Journal of Psychiatric Research (1961-1972) and (1985-1996).
10. Social Psychiatry (1966-1987).
11. Social Psychiatry & Psychiatric Epidemiology (1988-1996).
Appendix 4. Data collection and analysis methods used for the original review
Selection of studies
In the original version of this review, Sarah Stockton, Librarian at the University of Oxford, conducted the systematic search for trials.
Two out of TTS, EA, ET, and KH then independently screened the titles of identified trials for relevancy. A distinction was made
between:
1) eligible studies, in which any psychological and/or psychopharmacological treatment was compared with a control (e.g., standard or
less intensive types of aftercare or medication), and;
2) general treatment studies, without any control treatment.
A second screening was then undertaken in which two of TTS, EA, ET, and KH independently screened the full text of relevant studies
with reference to the following inclusion criteria:
1. All participants must have engaged in SH (i.e., self-poisoning or self-injury) shortly prior to randomisation;
2. Studies must have reported the number of participants engaging in a repeat episode of SH as an outcome measure;
3. Study participants must have been randomised to the treatment and control groups.
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Data extraction and management
Data extraction was carried out by EA and a second member of the review group (TTS, ET, or KH) using a standardised data extraction
form.Members of the review team extracted data independently fromone another.Disputes were resolved through consensus discussions
with a third member of the review group with assistance from the CCDAN editorial base.
We extracted data from each eligible trial concerning the characteristics of patients, the details of the interventions used, and information
on the number of participants engaging in a repeat episode of SH during the follow-up period. Where these details were unclear,
corresponding authors were contacted to provide additional clarification.
Assessment of risk of bias
For the original version of this review, the quality of the studies was rated by three independent review authors (EA and ET plus another
member of the review group). Review authors were blind to authorship according to the recommended Cochrane criteria for quality
assessment (Sackett 1997).
Given that the quality of concealment of allocation can affect the results of trials (Schultz 1995), studies were assigned a quality of
concealment rating ranging from C (poor quality) to A (high quality). Trials rated as inadequately concealed, for example via reference
to an open random number table, were given a rating of C. Trials that did not provide adequate details about how the randomisation
procedure was carried out were given a rating of B, and trials that were deemed to have taken adequate measures to conceal allocation,
for example through the use of serially numbered, opaque, sealed envelopes or numbered or coded bottles or containers, were rated as
A quality. Where the concealment of allocation was not clearly reported (i.e., where trials were initially in category B), we contacted
corresponding authors for more information. Where raters disagreed as to the category to which a trial had been allocated, the final
rating was made by consensus discussion in consultation with TTS, KH, and a third member of the review group.
Measures of treatment effect
RevMan version 3.0, was used to calculate summary odds ratios and accompanying 95% CIs for the number of participants engaging
in a repeat episode of SH during the follow-up period.
Unit of analysis issues
1. Cluster trials
Clustering was an issue in one included study, however, as the authors reported adjusting for the effects of clustering in their primary
analyses, we reproduced the data from this study as if it came from a non-cluster randomised study.
2. Studies with multiple treatment groups
One included study presented data for multiple treatment groups (Hirsch 1982). As both treatment groups were prescribed antide-
pressants in this study, we combined the data from these two treatment arms.
Dealing with missing data
Where data on the primary outcome measure were incomplete or excluded from the study, corresponding author(s) were contacted
to obtain further information. Some authors used intention to treat analyses to account for missing data using a variety of different
methods which was discussed within the ’Risk of bias’ tables. We as review authors did not attempt to impute data for those studies in
which intention-to-treat analyses had not been conducted, however. Instead, the effects of missing data were discussed in the text of
the review.
Assessment of heterogeneity
Clinical heterogeneity was examined using the Chi2 statistic. Where this statistic was significant, potential causes of heterogeneity were
investigated as outlined in the ”Subgroup analysis and investigation of heterogeneity“ section.
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Assessment of reporting biases
To assess whether any meta-analysis reported in the review were affected by reporting bias, we planned to construct funnel plots to
investigate the likelihood that the results of our meta-analysis were affected by reporting bias. We were unable to undertake these
analyses, however, due to the very small number of trials included in our meta-analyses.
Data synthesis
The Mantel-Haenszel fixed-effect method was used to calculate pooled summary ORs and accompanying 95% CIs.
Subgroup analysis and investigation of heterogeneity
In analyses resulting in significant heterogeneity, as indicated by the Chi2 statistic, an investigation into the source of this heterogeneity
was conducted. We had planned to conduct subgroup analyses by repeater status and gender, however there were insufficient studies
with appropriate data to enable these analyses to be undertaken.
Sensitivity analysis
Sensitivity analyses were undertaken where appropriate (e.g., in relation to risk of bias of included trials in the relative intensity of
treatment).
WH A T ’ S N E W
Last assessed as up-to-date: 2 September 2014.
Date Event Description
25 June 2015 New citation required but conclusions have not changed Review updated
25 June 2015 New search has been performed Original review CD001764 was split into three and up-
dated; no new studies were identified for this review, but
methodology was updated
C O N T R I B U T I O N S O F A U T H O R S
KH had the idea for the review. All authors extracted data and assessed risk of bias for included trials. Both TTS and KW conducted
the statistical analyses. KH, TTS, and KW wrote the initial version of the report and all authors contributed to the writing of drafts.
All authors also approved the final version of the review for publication.
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D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• University Department of Psychiatry, Warneford Hospital, Oxford, UK.
• Oxford Health NHS Foundation Trust, UK.
External sources
• NHS Executive Anglia and Oxford Research and Development Program, UK.
• NIHR Service Delivery and Organisation programme, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the original protocol for this review, we planned to assess dichotomous outcome data (i.e., repetition of self-harm and suicide) using
the Peto odds ratio. Following revisions to iterations of the Cochrane Handbook (Higgins 2003) and new statistical advice, however,
we have instead used the Mantel Haenzel method in this update. For this version of the review we have also expanded the range of
outcomes assessed to include depression, hopelessness, problem-solving, and suicidal ideation. We have also used the I2 statistic, rather
than the Chi2 test, to summarise between-study heterogeneity in this version in light of revisions to the Cochrane Handbook (Higgins
2003).
We also planned to assess methodological quality of included trials by the means recommended by the contemporary version of
the Cochrane Handbook (Higgins 2003). For this version of the review, we have therefore created ’Risk of bias’ tables as per current
recommendations. We have also refined the unit of analysis section, as per current recommendations, to include Zelen designed trials
and trials that report adjusted effect sizes.
For the first comparison, a post hoc analysis was performed to assess repetition for all three trials at the last follow-up (i.e., 12 weeks,
six months, and 12 months) and by drug type (i.e., mianserin, nomifensine, and paroxetine).
We have also added four sensitivity analyses: one for trials which employed Zelen’s method of randomisation; one for trials that
contributed to substantial (> 75%) levels of heterogeneity; one for trials that specifically recruited individuals diagnosed with borderline
personality disorder; and a fourth for trials that included a small minority (< 15% ) of adolescent participants.
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